

Large Group, Self-Funded and Small Group Transitional Formulary

Effective December 1, 2022



Understanding your formulary

What is a formulary?

A formulary is a list of prescribed medications chosen by your plan for their safety, cost and effectiveness. Medications are listed by categories or classes and are placed into cost levels known as tiers. The formulary includes both brand-name and generic prescription medications approved by the U.S. Food and Drug Administration (FDA).

How do I use my formulary?

You and your doctor can consult the formulary to help you select the most cost-effective prescription medications. This guide tells you if a medication is generic or brand name, and if special rules apply. Bring this list with you when you see your doctor. If you have questions on how your medication is covered, call the Customer Service number on the back of your ID card or visit firstcarolinacare.com.

What are tiers?

Tiers are the different cost levels you pay for a medication. Generally, the higher your medication's tier, the more you'll pay out of pocket for it.

When does the formulary change?

- Medications may move to a lower tier at any time.
- Medications may move to a higher tier when a generic equivalent becomes available.
- Medications may move to a higher tier or be excluded from coverage during the year as other formulary alternatives become available.

When a medication changes tiers, you may have to pay a different amount for that medication.

Why are some medications excluded from coverage?

A medication may be excluded from coverage under your pharmacy benefit when it works the same as or similar to another prescription or over-the-counter (OTC) medication.

What if I don't agree with a decision about an excluded medication?

You (or your authorized representative) and your doctor can ask for a coverage request by calling the Customer Service number on the back of your ID card.

About this formulary

Where differences exist between this formulary and your benefit plan documents, the benefit plan documents rule. This may not be a complete list of medications, and not all medications listed may be covered by your plan. Please look at the benefit plan documents provided by your employer or plan sponsor for full details.

Medication tips

What is the difference between brand-name and generic medications?

Generic medications contain the same active ingredients (what makes the medication work) as brand-name medications, but they often cost less. Once the patent for a brand-name medication ends, the FDA can approve a generic version with the same active ingredients. If you choose a brand-name medication after a generic version is available, you may pay the brand-name copayment plus the cost difference between the brand-name and generic medication. These medications will have a comment saying “Brand penalty applies” in the notes section.

Over-the-counter (OTC) medications

An OTC medication may be the right treatment option for some conditions. Talk to your doctor about available OTC options. Even though these medications may not be covered by your pharmacy benefit, they may cost less than a prescription medication.

What if my doctor writes a brand-name prescription?

If your doctor gives you a prescription for a brand-name medication, ask if a generic equivalent or lower-cost option is available and could be right for you. Generic medications are usually your lowest-cost option.

Reading your formulary

The formulary gives you choices so you and your doctor can determine your best course of treatment. In this formulary, brand-name medications are shown in UPPERCASE (for example, CLOBEX) and generic medications in lowercase (for example, clobetasol).

Tier Information

Using lower tier or preferred medications can help you pay your lowest out-of-pocket cost. Your plan may have multiple or no tiers. Your plan may have less than 6 drug tiers with some of the tiers listed below combined and available at the same copayment. For closed-formulary or restrictive formularies select medications may be excluded unless an exception is requested and approved. Details of your pharmacy benefits can be found in your plan documents. Please note: If you have a high-deductible plan, the tier cost levels will apply once you hit your deductible.

| Drug Tier | Drug Tier Description | Helpful Tips |
|-----------------------------|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Preventive | Brands and generics used for preventive care | No out-of-pocket cost. Deductible does not apply |
| Tier 1 | Preferred generics | Low out-of-pocket cost |
| Tier 2 | Non-preferred generics | Most generic drugs |
| Tier 3 | Preferred brands | Many brands have lower-cost generic options |
| Tier 4 | Non-preferred brands | Many brands have lower-cost generic options |
| Tier 5 | Preferred specialty pharmacy or medical | May be limited to a specialty pharmacy. Drugs administered in a doctor's office, clinic, hospital, or outpatient infusion center are covered under the medical benefit.* |
| Tier 6 | Non-preferred specialty pharmacy or medical | May be limited to a specialty pharmacy. Drugs administered in a doctor's office, clinic, hospital, or outpatient infusion center are covered under the medical benefit.* |
| General Medical (GM) | Medical benefit | Provided and administered in a doctor's office or hospital and not covered by the pharmacy benefit |

*Drugs covered under the medical benefit have copays or coinsurance as outlined in your plan documents.

Drug list Information

In this drug list, some medications are noted with letters next to them to help you see which ones may have coverage requirements or limits. Your benefit plan determines how these medications may be covered for you.

| | |
|------------|-------------------------------------------------------------------------------------------------------------------------------|
| AL | Age Limit – Based on government or manufacturer guidelines, these medications are only covered for certain age groups. |
| PA | Prior Authorization – Your doctor is required to provide additional information to determine coverage. |
| PV | Preventive – These medications are covered at \$0 under preventive benefit. |
| PV* | Preventive* – These medications may be covered as preventive care if you meet the guidelines based on your plan. |
| QL | Quantity Limit – Medication may be limited to a certain quantity. |
| ST | Step Therapy – Trial of lower-cost medication(s) is required before a higher-cost medication can be covered. |

First Carolina Care

Table of Contents

| | | | |
|-----------------------------------------------------------------------------------|-----|------------------------------------------------------------------------------------------------|-----|
| Analgesics - Drugs for Pain | 9 | Gastrointestinal Agents - Drugs for Acid Reflux and Ulcer | 151 |
| Analgesics - Drugs for Pain and Inflammation | 6 | Gastrointestinal Agents - Drugs for Bowel, Intestine and Stomach Conditions | 152 |
| Anesthetics | 17 | Genetic or Enzyme Disorder - Drugs for Replacement, Modification, Treatment.. | 157 |
| Anti-Addiction / Substance Abuse Treatment Agents | 22 | Genitourinary Agents - Drugs for Bladder, Genital and Kidney Conditions | 159 |
| Antibacterials | 23 | Genitourinary Agents - Drugs for Prostate Conditions | 163 |
| Anticoagulants | 35 | Hormonal Agents - Adrenal | 164 |
| Anticonvulsants - Drugs for Seizures | 37 | Hormonal Agents - Men's Health | 166 |
| Antidementia Agents - Drugs for Alzheimer's Disease and Dementia | 42 | Hormonal Agents - Pituitary | 167 |
| Antidepressants | 43 | Hormonal Agents - Prostaglandins | 171 |
| Antiemetics - Drugs for Nausea and Vomiting | 46 | Hormonal Agents - Selective Estrogen Receptor Modifying Agents | 171 |
| Antifungals | 48 | Hormonal Agents - Sex Hormones and Birth Control | 171 |
| Antigout Agents | 51 | Hormonal Agents - Thyroid | 181 |
| Antimigraine Agents | 52 | Immunological Agents - Drugs for Immune System Stimulation or Suppression | 182 |
| Antimyasthenic Agents | 54 | Immunological Agents - Drugs for Vaccination | 191 |
| Antimycobacterials | 55 | Inflammatory Bowel Disease Agents | 196 |
| Antineoplastics - Drugs for Cancer | 55 | Metabolic Bone Disease Agents - Drugs for Osteoporosis | 197 |
| Antiparasitics | 71 | Metabolic Bone Disease Agents - Other.. | 198 |
| Antiparkinson Agents | 72 | Miscellaneous Therapeutic Agents | 199 |
| Antiplatelets | 74 | Ophthalmic Agents - Drugs for Eye Allergy, Infection and Inflammation | 216 |
| Antipsychotics - Drugs for Mood Disorders | 75 | Ophthalmic Agents - Drugs for Glaucoma | 220 |
| Antivirals | 78 | Ophthalmic Agents - Drugs for Miscellaneous Eye Conditions | 222 |
| Anxiolytics - Drugs for Anxiety | 84 | Otic Agents - Drugs for Ear Conditions... | 226 |
| Bipolar Agents - Drugs for Mood Disorders | 86 | Respiratory Tract / Pulmonary Agents - Drugs for Allergies, Cough, Cold | 226 |
| Blood Products and Modifiers - Drugs for Blood Disorders | 86 | Respiratory Tract / Pulmonary Agents - Drugs for Asthma and Other Lung Conditions | 229 |
| Cardiovascular Agents - Drugs for Heart and Circulation Conditions | 92 | Respiratory Tract / Pulmonary Agents - Drugs for Cystic Fibrosis | 234 |
| Central Nervous System Agents - Drugs for Attention Deficit Disorder | 109 | Respiratory Tract / Pulmonary Agents - Drugs for Pulmonary Hypertension | 235 |
| Central Nervous System Agents - Drugs for Multiple Sclerosis | 113 | Skeletal Muscle Relaxants - Drugs for Muscle Pain and Spasm | 237 |
| Central Nervous System Agents - Miscellaneous | 115 | Sleep Disorder Agents | 238 |
| Dental and Oral Agents - Drugs for Mouth and Throat Conditions | 116 | Index of Drugs | 240 |
| Dermatological Agents - Drugs for Skin Conditions | 118 | | |
| Dermatological Agents - Drugs to Treat Skin Conditions | 128 | | |
| Diabetes - Antidiabetic Agents | 128 | | |
| Diabetes - Glucose Monitoring | 132 | | |
| Diabetes - Glycemic Agents | 133 | | |
| Diabetes - Insulins | 133 | | |
| Electrolytes / Minerals / Metals / Vitamins | 136 | | |

| Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------|-----------|-----------------------|
| Analgesics - Drugs for Pain and Inflammation | | |
| ACTIVE-KETOPROFEN EXTERNAL CREAM 5 % | 4 | |
| adult aspirin regimen oral tablet delayed release 81 mg | PV | |
| ANAPROX DS ORAL TABLET 550 MG | 4 | Brand penalty applies |
| ANJESO INTRAVENOUS INJECTABLE 30 MG/ML | GM | |
| ARTHROTEC ORAL TABLET DELAYED RELEASE 50-0.2 MG, 75-0.2 MG | 4 | Brand penalty applies |
| aspirin adult low dose oral tablet delayed release 81 mg | PV | |
| aspirin adult low strength oral tablet delayed release 81 mg | PV | |
| aspirin childrens oral tablet chewable 81 mg | PV | |
| aspirin ec low dose oral tablet delayed release 81 mg | PV | |
| aspirin ec low strength oral tablet delayed release 81 mg | PV | |
| aspirin low dose oral tablet chewable 81 mg | PV | |
| aspirin low dose oral tablet delayed release 81 mg | PV | |
| aspirin oral tablet delayed release 81 mg | PV | |
| aspirin regimen oral tablet delayed release 81 mg | PV | |

| Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------|-----------|-----------------------|
| BAYER ASPIRIN EC LOW DOSE ORAL TABLET DELAYED RELEASE 81 MG | 4 | |
| CALDOLOR INTRAVENOUS SOLUTION 800 MG/8ML | GM | |
| CAPSFENAC PAK EXTERNAL THERAPY PACK 1.5 & 0.025 % | 4 | |
| CAPSINAC EXTERNAL THERAPY PACK 0.025-1.5 % | 4 | |
| CATAFLAM ORAL TABLET 50 MG | 4 | Brand penalty applies |
| CELEBREX ORAL CAPSULE 100 MG, 200 MG, 400 MG, 50 MG | 4 | Brand penalty applies |
| celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg | 2 | |
| DAYPRO ORAL TABLET 600 MG | 4 | Brand penalty applies |
| DICLOFENAC PATCH EXTERNAL PATCH 1.3 % | 4 | ST |
| diclofenac potassium oral tablet 25 mg | 4 | |
| diclofenac potassium oral tablet 50 mg | 2 | |
| diclofenac sodium er oral tablet extended release 24 hour 100 mg | 2 | |
| diclofenac sodium external gel 1 % | 2 | |
| diclofenac sodium oral tablet delayed release 25 mg | 2 | |
| diclofenac sodium oral tablet delayed release 50 mg, 75 mg | 1 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------------|-----------|-----------------------|
| diclofenac-misoprostol oral tablet delayed release 50-0.2 mg, 75-0.2 mg | 2 | |
| DICLOFEX DC EXTERNAL THERAPY PACK 1.5-0.025 % | 4 | |
| DICLOHEAL-60 EXTERNAL THERAPY PACK 1.5 & 0.025 % | 4 | |
| DICLOSAICIN EXTERNAL THERAPY PACK 1.5 & 0.025 %, 1.5-0.025 % | 4 | |
| DICLOSTREAM EXTERNAL THERAPY PACK 1.5-10 % | 4 | |
| DICLOVIX EXTERNAL KIT 1.5 & 2-2.5-4 % | 4 | |
| diflunisal oral tablet 500 mg | 2 | |
| DIMENTHO EXTERNAL THERAPY PACK 1.5 & 10 % | 4 | |
| EC-NAPROSYN ORAL TABLET DELAYED RELEASE 375 MG, 500 MG | 4 | Brand penalty applies |
| ec-naproxen oral tablet delayed release 375 mg, 500 mg | 2 | |
| ENOVARX-IBUPROFEN EXTERNAL CREAM 10 % | 4 | |
| EQUAPAX/IBUPROFEN/MINREX ORAL THERAPY PACK 800 MG | 4 | |
| etodolac er oral tablet extended release 24 hour 400 mg, 500 mg, 600 mg | 2 | |
| etodolac oral capsule 200 mg, 300 mg | 2 | |

| Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------|-----------|-----------------------|
| etodolac oral tablet 400 mg, 500 mg | 2 | |
| FBL KIT EXTERNAL CREAM 15-4-5 % | 4 | |
| FELDENE ORAL CAPSULE 10 MG, 20 MG | 4 | Brand penalty applies |
| fenoprofen calcium oral capsule 200 mg, 400 mg | 2 | |
| fenoprofen calcium oral tablet 600 mg | 2 | |
| fenortho oral capsule 200 mg | 2 | |
| FLECTOR EXTERNAL PATCH 1.3 % | 4 | ST |
| flurbiprofen oral tablet 100 mg, 50 mg | 2 | |
| goodsense aspirin low dose oral tablet delayed release 81 mg | PV | |
| ibuprofen lysine intravenous solution 10 mg/ml | GM | |
| ibuprofen oral suspension 100 mg/5ml | 2 | |
| ibuprofen oral tablet 400 mg, 600 mg, 800 mg | 2 | |
| ICLOFENAC CP EXTERNAL THERAPY PACK 0.025-1.5 % | 4 | |
| INDOCIN ORAL SUSPENSION 25 MG/5ML | 4 | |
| INDOCIN RECTAL SUPPOSITORY 50 MG | 3 | |
| indomethacin er oral capsule extended release 75 mg | 2 | |
| indomethacin oral capsule 25 mg, 50 mg | 2 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------------------|-----------|------------------------|
| indomethacin sodium intravenous solution reconstituted 1 mg | GM | |
| KAPZIN DC EXTERNAL THERAPY PACK 0.025-1.5 % | 4 | |
| ketoprofen er oral capsule extended release 24 hour 200 mg | 2 | |
| ketoprofen oral capsule 25 mg, 50 mg, 75 mg | 2 | |
| ketorolac tromethamine oral tablet 10 mg | 2 | QL (20 EA per 30 days) |
| KETOROLAC-BUPIV-KETAMINE INJECTION SOLUTION PREFILLED SYRINGE 60-150-60 MG/50ML | GM | |
| KETOROLAC-ROPIV-KETAMINE INJECTION SOLUTION PREFILLED SYRINGE 15-100-30 MG/50ML | GM | |
| LODINE ORAL TABLET 400 MG | 4 | Brand penalty applies |
| meclofenamate sodium oral capsule 100 mg, 50 mg | 2 | |
| mefenamic acid oral capsule 250 mg | 2 | |
| MELOXICAM ORAL SUSPENSION 7.5 MG/5ML | 4 | |
| meloxicam oral tablet 15 mg, 7.5 mg | 1 | |
| mm aspirin oral tablet delayed release 81 mg | PV | |
| MOBIC ORAL TABLET 15 MG, 7.5 MG | 4 | Brand penalty applies |

| Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------------|-----------|-----------------------|
| nabumetone oral tablet 500 mg, 750 mg | 2 | |
| NALFON ORAL CAPSULE 400 MG | 4 | Brand penalty applies |
| NALFON ORAL TABLET 600 MG | 4 | Brand penalty applies |
| NAPRELAN ORAL TABLET EXTENDED RELEASE 24 HOUR 375 MG, 500 MG | 4 | Brand penalty applies |
| NAPRELAN ORAL TABLET EXTENDED RELEASE 24 HOUR 750 MG | 4 | |
| NAPRO EXTERNAL CREAM 15 % | 4 | |
| NAPROSYN ORAL SUSPENSION 125 MG/5ML | 4 | Brand penalty applies |
| NAPROSYN ORAL TABLET 500 MG | 4 | Brand penalty applies |
| naproxen oral suspension 125 mg/5ml | 2 | |
| naproxen oral tablet 250 mg, 375 mg, 500 mg | 2 | |
| naproxen oral tablet delayed release 375 mg, 500 mg | 2 | |
| naproxen sodium er oral tablet extended release 24 hour 375 mg, 500 mg | 2 | |
| naproxen sodium er tablet extended release 24 hour 750 mg oral 750 mg | 2 | |
| NAPROXEN SODIUM ER TABLET EXTENDED RELEASE 24 HOUR 750 MG ORAL 750 MG | 4 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------|-----------|-----------------------|
| naproxen sodium oral tablet 275 mg, 550 mg | 2 | |
| NEOPROFEN INTRAVENOUS SOLUTION 10 MG/ML | GM | |
| NUDICLO SOLUPAK EXTERNAL THERAPY PACK 1.5 & 0.025 % | 4 | |
| oxaprozin oral tablet 600 mg | 2 | |
| PENNSAICIN EXTERNAL THERAPY PACK 1.5 & 0.025 % | 4 | |
| piroxicam oral capsule 10 mg, 20 mg | 2 | |
| RELAFEN ORAL TABLET 500 MG, 750 MG | 4 | Brand penalty applies |
| salsalate oral tablet 500 mg, 750 mg | 2 | |
| ST JOSEPH LOW DOSE ORAL TABLET CHEWABLE 81 MG | 4 | |
| ST JOSEPH LOW DOSE ORAL TABLET DELAYED RELEASE 81 MG | 4 | |
| sulindac oral tablet 150 mg, 200 mg | 2 | |
| SURE RESULT DSS PREMIUM PACK EXTERNAL THERAPY PACK 1.5 & 0.025 % | 4 | |
| tolmetin sodium oral capsule 400 mg | 2 | |
| tolmetin sodium oral tablet 600 mg | 2 | |
| VOLTAREN EXTERNAL GEL 1 % | 4 | |
| ZICLOCIN EXTERNAL THERAPY PACK 1.5 & 0.025 % | 4 | |

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------------------|-----------|---------------------------|
| ZICLOPRO EXTERNAL THERAPY PACK 1.5 & 0.025 % | 4 | |
| ZYNRELEF INJECTION SOLUTION 200-6 MG/7ML, 400-12 MG/14ML | GM | |
| Analgesics - Drugs for Pain | | |
| acetaminophen intravenous solution 10 mg/ml, 1000 mg/100ml | GM | |
| ACETAMINOPHEN INTRAVENOUS SOLUTION PREFILLED SYRINGE 100 MG/10ML | GM | |
| acetaminophen-codeine #2 oral tablet 300-15 mg | 2 | |
| acetaminophen-codeine #3 oral tablet 300-30 mg | 2 | |
| acetaminophen-codeine #4 oral tablet 300-60 mg | 2 | |
| acetaminophen-codeine oral solution 120-12 mg/5ml | 2 | |
| acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg, 300-60 mg | 2 | |
| ACTIQ BUCCAL LOZENGE ON A HANDLE 1200 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG | 4 | PA; Brand penalty applies |
| alfentanil hcl intravenous solution 1000 mcg/2ml, 2500 mcg/5ml | GM | |
| apap-caff-dihydrocodeine oral capsule 320.5-30-16 mg | 2 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|----------------------------------------------------------------------------------------------|-----------|------------------------|
| ARYMO ER ORAL TABLET EXTENDED RELEASE ABUSE-DETERRENT 15 MG, 30 MG, 60 MG | 4 | PA |
| ascomp-codeine oral capsule 50-325-40-30 mg | 2 | |
| bac oral tablet 50-325-40 mg | 2 | |
| BELBUCA BUCCAL FILM 150 MCG, 300 MCG, 450 MCG, 600 MCG, 75 MCG, 750 MCG, 900 MCG | 4 | QL (60 EA per 30 days) |
| BUPAP ORAL TABLET 50-300 MG | 4 | Brand penalty applies |
| BUPRENEX INJECTION SOLUTION 0.3 MG/ML | GM | |
| buprenorphine hcl injection solution 0.3 mg/ml | GM | |
| buprenorphine transdermal patch weekly 10 mcg/hr, 15 mcg/hr, 20 mcg/hr, 5 mcg/hr, 7.5 mcg/hr | 2 | |
| butalbital-acetaminophen capsule 50-300 mg oral 50-300 mg | 2 | |
| BUTALBITAL-ACETAMINOPHEN CAPSULE 50-300 MG ORAL 50-300 MG | 2 | |
| butalbital-acetaminophen oral tablet 50-300 mg, 50-325 mg | 2 | |
| butalbital-apap-caff-cod oral capsule 50-300-40-30 mg, 50-325-40-30 mg | 2 | |

| Drug Name | Drug Tier | Notes |
|----------------------------------------------------------------------------------------|-----------|-----------------------|
| butalbital-apap-caffeine oral capsule 50-300-40 mg, 50-325-40 mg | 2 | |
| butalbital-apap-caffeine oral tablet 50-325-40 mg | 2 | |
| butalbital-asa-caff-codeine oral capsule 50-325-40-30 mg | 2 | |
| butalbital-aspirin-caffeine oral capsule 50-325-40 mg | 2 | |
| butalbital-aspirin-caffeine oral tablet 50-325-40 mg | 2 | |
| butorphanol tartrate injection solution 1 mg/ml, 2 mg/ml | GM | |
| butorphanol tartrate nasal solution 10 mg/ml | 2 | |
| BUTRANS TRANSDERMAL PATCH WEEKLY 10 MCG/HR, 15 MCG/HR, 20 MCG/HR, 5 MCG/HR, 7.5 MCG/HR | 4 | Brand penalty applies |
| carisoprodol-aspirin-codeine oral tablet 200-325-16 mg | 2 | |
| clonidine hcl (analgesia) epidural solution 100 mcg/ml, 500 mcg/ml | 6 | Specialty Medical |
| codeine sulfate oral tablet 15 mg, 30 mg, 60 mg | 2 | |
| DEMEROL INJECTION SOLUTION 100 MG/ML, 25 MG/ML, 50 MG/ML, 75 MG/ML | GM | |
| DILAUDID INJECTION SOLUTION 1 MG/ML, 2 MG/ML | GM | |
| DILAUDID ORAL LIQUID 1 MG/ML | 4 | Brand penalty applies |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------------------------------------------------|-----------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------|
| DILAUDID ORAL TABLET 2 MG, 4 MG, 8 MG | 4 | Brand penalty applies | fentanyl citrate (pf) injection solution cartridge 100 mcg/2ml | GM | |
| DSUVIA SUBLINGUAL TABLET SUBLINGUAL 30 MCG | 4 | | fentanyl citrate buccal lozenge on a handle 1200 mcg, 1600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg | 2 | PA |
| DURACLON EPIDURAL SOLUTION 100 MCG/ML | 6 | Specialty Medical | FENTANYL CITRATE BUCCAL TABLET 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG | 4 | PA |
| DURAGESIC-100 TRANSDERMAL PATCH 72 HOUR 100 MCG/HR | 4 | PA; Brand penalty applies | FENTANYL CITRATE INJECTION SOLUTION 1500 MCG/30ML | GM | |
| DURAGESIC-12 TRANSDERMAL PATCH 72 HOUR 12 MCG/HR | 4 | PA; Brand penalty applies | FENTANYL CITRATE INJECTION SOLUTION PREFILLED SYRINGE 250 MCG/5ML | GM | |
| DURAGESIC-25 TRANSDERMAL PATCH 72 HOUR 25 MCG/HR | 4 | PA; Brand penalty applies | FENTANYL CITRATE INTRAVENOUS SOLUTION 1500 MCG/30ML, 2500 MCG/50ML, 5000 MCG/100ML | GM | |
| DURAGESIC-50 TRANSDERMAL PATCH 72 HOUR 50 MCG/HR | 4 | PA; Brand penalty applies | FENTANYL CITRATE INTRAVENOUS SOLUTION PREFILLED SYRINGE 10 MCG/ML, 100 MCG/10ML, 100 MCG/2ML, 1000 MCG/20ML, 1250 MCG/25ML, 1500 MCG/30ML, 20 MCG/2ML, 250 MCG/5ML, 2500 MCG/50ML, 2750 MCG/55ML, 50 MCG/5ML, 50 MCG/ML, 500 MCG/50ML | GM | |
| DURAGESIC-75 TRANSDERMAL PATCH 72 HOUR 75 MCG/HR | 4 | PA; Brand penalty applies | fentanyl citrate pf injection solution prefilled syringe 50 mcg/ml | GM | |
| duramorph injection solution 0.5 mg/ml, 1 mg/ml | GM | | | | |
| endocet oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg | 2 | | | | |
| ESGIC ORAL CAPSULE 50-325-40 MG | 4 | Brand penalty applies | | | |
| ESGIC ORAL TABLET 50-325-40 MG | 4 | Brand penalty applies | | | |
| fentanyl citrate (pf) injection solution 100 mcg/2ml, 1000 mcg/20ml, 250 mcg/5ml, 2500 mcg/50ml, 500 mcg/10ml | GM | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------|
| fentanyl citrate solution prefilled syringe 100 mcg/2ml injection 100 mcg/2ml | GM | | fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr | 2 | PA |
| FENTANYL CITRATE SOLUTION PREFILLED SYRINGE 100 MCG/2ML INJECTION 100 MCG/2ML | GM | | FENTANYL-BUPIVACAINE-NACL EPIDURAL SOLUTION 0.2-0.1-0.9 MG/100ML-%, 0.2-0.125-0.9 MG/100ML-%, 0.5-0.0625-0.9 MG/250ML-%, 0.5-0.1-0.9 MG/250ML-%, 0.5-0.125-0.9 MG/250ML-%, 0.8-0.1667-0.9 MG/200ML-%, 1-0.125-0.9 MG/250ML-% | GM | |
| FENTANYL CITRATE-NACL INJECTION SOLUTION 1-0.9 MG/100ML-%, 2.5-0.9 MG/250ML-% | GM | | FENTANYL-BUPIVACAINE-NACL EPIDURAL SOLUTION PREFILLED SYRINGE 0.1-0.125-0.9 MG/50ML-% | GM | |
| FENTANYL CITRATE-NACL INTRAVENOUS SOLUTION 1-0.9 MG/100ML-%, 1.25-0.9 MG/250ML-%, 2-0.9 MG/100ML-%, 2.5-0.9 MG/250ML-% | GM | | FENTANYL-BUPIVACAINE-NACL INJECTION SOLUTION 2-0.125-0.9 MCG/ML-%-% | GM | |
| FENTANYL CITRATE-NACL INTRAVENOUS SOLUTION PREFILLED SYRINGE 10-0.9 MCG/2ML-%, 10-0.9 MCG/ML-%, 100-0.9 MCG/10ML-%, 1000-0.9 MCG/50ML-%, 5-0.9 MCG/ML-%, 550-0.9 MCG/55ML-% | GM | | FENTORA BUCCAL TABLET 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG | 4 | PA |
| FENTANYL CIT-ROPIVACAINE-NACL EPIDURAL SOLUTION 0.2-0.1-0.9 MG/100ML-%, 0.3-0.2-0.9 MG/150ML-%, 0.4-0.1-0.9 MG/200ML-%, 0.4-0.2-0.9 MG/200ML-%, 0.5-0.2-0.9 MG/250ML-% | GM | | FIORICET ORAL CAPSULE 50-300-40 MG | 4 | Brand penalty applies |
| | | | FIORICET/CODEINE ORAL CAPSULE 50-300-40-30 MG | 4 | Brand penalty applies |
| | | | FIORINAL ORAL CAPSULE 50-325-40 MG | 4 | Brand penalty applies |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------------------------------------------------------------|-----------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------|
| FIORINAL/CODEINE #3 ORAL CAPSULE 50-325-40-30 MG | 4 | Brand penalty applies | hydromorphone hcl pf injection solution 1 mg/ml, 10 mg/ml, 2 mg/ml, 4 mg/ml, 50 mg/5ml, 500 mg/50ml | GM | |
| hydrocodone bitartrate er oral capsule extended release 12 hour 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg | 2 | PA; QL (60 EA per 30 days) | hydromorphone hcl rectal suppository 3 mg | 2 | |
| hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrent 100 mg, 120 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg | 2 | PA | HYDROMORPHONE HCL SOLUTION 1 MG/ML INJECTION 1 MG/ML | GM | |
| hydrocodone-acetaminophen oral solution 10-325 mg/15ml, 2.5-108 mg/5ml, 5-217 mg/10ml, 7.5-325 mg/15ml | 2 | | hydromorphone hcl solution 1 mg/ml injection 1 mg/ml | GM | |
| hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg | 2 | | HYDROMORPHONE HCL-NACL INJECTION SOLUTION 20-0.9 MG/100ML-% | GM | |
| hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg, 7.5-200 mg | 2 | | HYDROMORPHONE HCL-NACL INJECTION SOLUTION PREFILLED SYRINGE 10-0.9 MG/50ML-%, 30-0.9 MG/30ML-% | GM | |
| hydromorphone hcl er oral tablet extended release 24 hour 12 mg, 16 mg, 32 mg, 8 mg | 2 | PA; QL (60 EA per 30 days) | HYDROMORPHONE HCL-NACL INTRAVENOUS SOLUTION 100-0.9 MG/50ML-%, 20-0.9 MG/100ML-%, 30-0.9 MG/30ML-% | GM | |
| HYDROMORPHONE HCL INJECTION SOLUTION 0.5 MG/ML | GM | | HYDROMORPHONE HCL-NACL INTRAVENOUS SOLUTION PREFILLED SYRINGE 0.2-0.9 MG/0.2ML-%, 0.5-0.9 MG/0.5ML-%, 1-0.9 MG/5ML-%, 1-0.9 MG/ML-%, 2-0.9 MG/ML-%, 25-0.9 MG/50ML-%, 50-0.9 MG/50ML-%, 55-0.9 MG/55ML-%, 6-0.9 MG/30ML-% | GM | |
| hydromorphone hcl injection solution 2 mg/ml, 4 mg/ml | GM | | | | |
| HYDROMORPHONE HCL INTRAVENOUS SOLUTION 0.2 MG/ML | GM | | | | |
| hydromorphone hcl oral liquid 1 mg/ml | 2 | | | | |
| hydromorphone hcl oral tablet 2 mg, 4 mg, 8 mg | 2 | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------------------------------------------|-----------|---------------------------|------------------------------------------------------------------------------------|-----------|-------|
| HYSINGLA ER ORAL TABLET ER 24 HOUR ABUSE-DETERRENT 100 MG, 120 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG | 4 | PA; Brand penalty applies | meperidine hcl oral tablet 50 mg | 2 | |
| INFUMORPH 200 INJECTION SOLUTION 200 MG/20ML (10 MG/ML) | GM | | methadone hcl injection solution 10 mg/ml | GM | |
| INFUMORPH 500 INJECTION SOLUTION 500 MG/20ML (25 MG/ML) | GM | | methadone hcl intensol oral concentrate 10 mg/ml | 2 | |
| KADIAN ORAL CAPSULE EXTENDED RELEASE 24 HOUR 10 MG, 100 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG, 80 MG | 4 | PA; Brand penalty applies | methadone hcl oral concentrate 10 mg/ml | 2 | |
| KADIAN ORAL CAPSULE EXTENDED RELEASE 24 HOUR 200 MG | 4 | PA | methadone hcl oral solution 10 mg/5ml, 5 mg/5ml | 2 | |
| LAZANDA NASAL SOLUTION 100 MCG/ACT, 300 MCG/ACT, 400 MCG/ACT | 4 | PA | methadone hcl oral tablet 10 mg, 5 mg | 2 | |
| levorphanol tartrate oral tablet 2 mg, 3 mg | 2 | | methadone hcl oral tablet soluble 40 mg | 2 | |
| LORTAB ORAL ELIXIR 10-300 MG/15ML | 4 | | METHADONE HCL-NACL INTRAVENOUS SOLUTION PREFILLED SYRINGE 1-0.9 MG/ML-% | GM | |
| MEDI-DERM-RX EXTERNAL CREAM 0.035-5-20 % | 4 | | METHADONE HCL-SODIUM CHLORIDE INTRAVENOUS SOLUTION PREFILLED SYRINGE 1-0.9 MG/ML-% | GM | |
| MEDROX-RX EXTERNAL OINTMENT 0.05-7-20 % | 4 | | methadose oral concentrate 10 mg/ml | 2 | |
| meperidine hcl injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml | GM | | methadose oral tablet soluble 40 mg | 2 | |
| meperidine hcl oral solution 50 mg/5ml | 2 | | methadose sugar-free oral concentrate 10 mg/ml | 2 | |
| | | | mitigo injection solution 200 mg/20ml (10 mg/ml), 500 mg/20ml (25 mg/ml) | GM | |
| | | | morphine sulfate (concentrate) oral solution 10 mg/0.5ml, 100 mg/5ml, 20 mg/ml | 2 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------------------------------------------------------|-----------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------------|
| morphine sulfate (pf) injection solution 0.5 mg/ml, 1 mg/ml, 10 mg/ml, 2 mg/ml, 4 mg/ml, 5 mg/ml, 8 mg/ml | GM | | MORPHINE SULFATE SOLUTION 1 MG/ML INTRAVENOUS 1 MG/ML | GM | |
| morphine sulfate (pf) intravenous solution 10 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml | GM | | morphine sulfate solution 1 mg/ml intravenous 1 mg/ml | GM | |
| morphine sulfate er beads oral capsule extended release 24 hour 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg | 2 | PA | MORPHINE SULFATE-NACL INJECTION SOLUTION PREFILLED SYRINGE 5-0.9 MG/5ML-% | GM | |
| morphine sulfate er oral capsule extended release 24 hour 10 mg, 100 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg | 2 | PA | MORPHINE SULFATE-NACL INTRAVENOUS SOLUTION 1-0.9 MG/ML-%, 100-0.9 MG/100ML-%, 250-0.9 MG/50ML-%, 500-0.9 MG/100ML-% | GM | |
| morphine sulfate er oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg | 2 | PA | MORPHINE SULFATE-NACL INTRAVENOUS SOLUTION PREFILLED SYRINGE 1-0.9 MG/ML-%, 150-0.9 MG/30ML-%, 2-0.9 MG/ML-%, 30-0.9 MG/30ML-%, 4-0.9 MG/ML-%, 55-0.9 MG/55ML-% | GM | |
| MORPHINE SULFATE INJECTION SOLUTION 1 MG/ML | GM | | MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 15 MG, 200 MG, 30 MG, 60 MG | 4 | PA; Brand penalty applies |
| morphine sulfate injection solution 2 mg/ml, 4 mg/ml, 5 mg/ml | GM | | nalbuphine hcl injection solution 10 mg/ml, 20 mg/ml | GM | |
| MORPHINE SULFATE INTRAVENOUS SOLUTION 0.5 MG/ML | GM | | NALOCET ORAL TABLET 2.5-300 MG | 4 | |
| morphine sulfate intravenous solution 10 mg/ml, 4 mg/ml, 8 mg/ml | GM | | NORCO ORAL TABLET 10-325 MG, 5-325 MG, 7.5-325 MG | 4 | Brand penalty applies |
| morphine sulfate oral solution 10 mg/5ml, 20 mg/5ml | 2 | | | | |
| morphine sulfate oral tablet 15 mg, 30 mg | 2 | | | | |
| morphine sulfate rectal suppository 10 mg, 20 mg, 30 mg, 5 mg | 2 | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------------------------------------------|-----------|-------|---------------------------------------------------------------------------------------------------------|-----------|-----------------------|
| NUCYNTA ER ORAL TABLET EXTENDED RELEASE 12 HOUR 100 MG, 150 MG, 200 MG, 250 MG, 50 MG | 4 | PA | oxycodone-aspirin oral tablet 4.8355-325 mg | 2 | |
| NUCYNTA ORAL TABLET 100 MG, 50 MG, 75 MG | 4 | ST | OXYCONTIN ORAL TABLET ER 12 HOUR ABUSE-DETERRENT 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG | 4 | PA |
| OLINVYK INTRAVENOUS SOLUTION 1 MG/ML, 2 MG/2ML, 30 MG/30ML | GM | | oxymorphone hcl er oral tablet extended release 12 hour 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg | 2 | PA |
| OXAYDO ORAL TABLET 5 MG, 7.5 MG | 4 | PA | oxymorphone hcl oral tablet 10 mg, 5 mg | 2 | |
| OXYCODONE HCL ER ORAL TABLET ER 12 HOUR ABUSE-DETERRENT 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG | 4 | PA | pentazocine-naloxone hcl oral tablet 50-0.5 mg | 2 | |
| oxycodone hcl oral capsule 5 mg | 2 | | PERCOCET ORAL TABLET 10-325 MG, 2.5-325 MG, 5-325 MG, 7.5-325 MG | 4 | Brand penalty applies |
| oxycodone hcl oral concentrate 100 mg/5ml | 2 | | PRIALT INTRATHECAL SOLUTION 100 MCG/ML, 500 MCG/20ML, 500 MCG/5ML | GM | |
| oxycodone hcl oral solution 5 mg/5ml | 2 | | PRIMLEV ORAL TABLET 10-300 MG, 5-300 MG, 7.5-300 MG | 4 | |
| oxycodone hcl oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg | 2 | | PROLATE ORAL TABLET 10-300 MG, 5-300 MG, 7.5-300 MG | 4 | |
| OXYCODONE-ACETAMINOPHEN ORAL SOLUTION 5-325 MG/5ML | 4 | ST | remifentanil hcl intravenous solution reconstituted 1 mg, 2 mg, 5 mg | GM | |
| OXYCODONE-ACETAMINOPHEN ORAL TABLET 10-300 MG, 2.5-300 MG, 5-300 MG, 7.5-300 MG | 4 | | ROXICODONE ORAL TABLET 15 MG, 30 MG, 5 MG | 4 | Brand penalty applies |
| oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg | 2 | | ROXYBOND ORAL TABLET ABUSE-DETERRENT 15 MG, 30 MG, 5 MG | 4 | PA |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------------------------------------------------------|-----------|-----------------------|
| SUBSYS SUBLINGUAL LIQUID 100 MCG, 1200 (600 X 2) MCG, 1600 (800 X 2) MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG | 4 | PA |
| sufentanil citrate intravenous solution 100 mcg/2ml, 250 mcg/5ml, 50 mcg/ml | GM | |
| TENCON ORAL TABLET 50-325 MG | 4 | |
| tramadol hcl er (biphasic) oral tablet extended release 24 hour 100 mg, 200 mg, 300 mg | 2 | ST |
| tramadol hcl er oral tablet extended release 24 hour 100 mg, 200 mg, 300 mg | 2 | ST |
| tramadol hcl oral tablet 100 mg, 50 mg | 2 | |
| tramadol-acetaminophen oral tablet 37.5-325 mg | 2 | |
| TREZIX ORAL CAPSULE 320.5-30-16 MG | 4 | Brand penalty applies |
| ULTIVA INTRAVENOUS SOLUTION RECONSTITUTED 1 MG, 2 MG, 5 MG | GM | |
| ULTRACET ORAL TABLET 37.5-325 MG | 4 | Brand penalty applies |
| ULTRAM ORAL TABLET 50 MG | 4 | Brand penalty applies |
| VANATOL LQ ORAL SOLUTION 50-325-40 MG/15ML | 4 | |
| VTOL LQ ORAL SOLUTION 50-325-40 MG/15ML | 4 | |

| Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------------------------------|-----------|---------------------------------------------------|
| XTAMPZA ER ORAL CAPSULE ER 12 HOUR ABUSE-DETERRENT 13.5 MG, 18 MG, 27 MG, 36 MG, 9 MG | 4 | PA |
| ZEBUTAL ORAL CAPSULE 50-325-40 MG | 4 | Brand penalty applies |
| ZOHYDRO ER ORAL CAPSULE EXTENDED RELEASE 12 HOUR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 50 MG | 4 | PA; Brand penalty applies; QL (60 EA per 30 days) |
| Anesthetics | | |
| 1ST MEDX-PATCH/ LIDOCAINE EXTERNAL PATCH 4-0.0375-5-20 % | 4 | |
| 7T LIDO EXTERNAL GEL 2 % | 4 | |
| AGONEAZE EXTERNAL KIT 2.5-2.5 % | 4 | |
| ANODYNE LPT EXTERNAL KIT 2.5-2.5 % | 4 | |
| ARTICADENT DENTAL INJECTION SOLUTION CARTRIDGE 4 %-1:100000, 4 %-1:200000 | GM | |
| bupivacaine fisiopharma injection solution 2.5 mg/ml, 5 mg/ml | GM | |
| bupivacaine hcl (pf) injection solution 0.25 %, 0.5 %, 0.75 % | GM | |
| BUPIVACAINE HCL INJECTION SOLUTION 0.125 % | GM | |
| bupivacaine hcl injection solution 0.25 %, 0.5 % | GM | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------------------------------|-----------|-------|---------------------------------------------------------------------------|-----------|------------------------|
| BUPIVACAINE HCL INJECTION SOLUTION PREFILLED SYRINGE 0.125 % (50 ML), 0.25 % (10 ML) | GM | | CLOROTEKAL INTRATHECAL SOLUTION 50 MG/5ML | GM | |
| BUPIVACAINE HCL-NACL EPIDURAL SOLUTION 0.125-0.9 % | GM | | COCAINE HCL NASAL SOLUTION 40 MG/ML | GM | |
| BUPIVACAINE HCL-NACL EPIDURAL SOLUTION PREFILLED SYRINGE 0.25-0.9 % | GM | | DERMACINRX EMPRICAINE EXTERNAL KIT 2.5-2.5 % | 4 | |
| bupivacaine in dextrose intrathecal solution 0.75-8.25 % | GM | | DERMACINRX LIDOGEL EXTERNAL GEL 2.8 % | 4 | |
| bupivacaine spinal intrathecal solution 0.75-8.25 % | GM | | ethyl chloride external aerosol | 2 | |
| bupivacaine-epinephrine (pf) injection solution 0.25% -1:200000, 0.5% - 1:200000 | GM | | EXPAREL INJECTION SUSPENSION 1.3 % | GM | |
| bupivacaine-epinephrine injection solution 0.25% - 1:200000, 0.5% - 1:200000 | GM | | glydo external prefilled syringe 2 % | 2 | |
| CARBOCAINE INJECTION SOLUTION 1 % | GM | | GOPRELTO NASAL SOLUTION 40 MG/ML | GM | |
| CETACAINE EXTERNAL AEROSOL 2-2-14 % | GM | | L.E.T. EXTERNAL SOLUTION 4-0.05-0.5 % | GM | |
| chloroprocaine hcl (pf) injection solution 2 %, 3 % | GM | | LETS KIT | 4 | |
| CITANEST FORTE DENTAL INJECTION SOLUTION 4% - 1:200000 | GM | | LEVATIO EXTERNAL PATCH 0.03-5 % | 4 | |
| CITANEST PLAIN DENTAL INJECTION SOLUTION 4 % | GM | | LIDO BDK EXTERNAL KIT 2.5-2.5 % | 4 | |
| | | | lidocaine external ointment 5 % | 2 | QL (50 GM per 30 days) |
| | | | lidocaine external patch 5 % | 2 | |
| | | | LIDOCAINE HCL (BUFFERED) INJECTION SOLUTION PREFILLED SYRINGE 100 MG/10ML | GM | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|----------------------------------------------------------------------------------------------------|-----------|-------|--------------------------------------------------------------------------------------------------------------------------------|-----------|-------|
| LIDOCAINE HCL (CARDIAC) INTRAVENOUS SOLUTION PREFILLED SYRINGE 100 MG/10ML, 200 MG/10ML, 60 MG/3ML | GM | | LIDOCAINE HCL INJECTION SOLUTION PREFILLED SYRINGE 10 MG/ML, 100 MG/10ML, 200 MG/10ML, 9 MG/ML | GM | |
| lidocaine hcl (cardiac) intravenous solution prefilled syringe 50 mg/5ml | GM | | LIDOCAINE HCL INTRADERMAL JET-INJECTOR 0.5 MG | 4 | |
| lidocaine hcl (cardiac) pf intravenous solution 100 mg/5ml | GM | | LIDOCAINE HCL SOLUTION 1 % INJECTION 1 % | GM | |
| lidocaine hcl (cardiac) pf intravenous solution prefilled syringe 100 mg/5ml, 50 mg/5ml | GM | | lidocaine hcl solution 1 % injection 1 % | GM | |
| lidocaine hcl (cardiac) solution prefilled syringe 100 mg/5ml intravenous 100 mg/5ml | GM | | LIDOCAINE HCL SOLUTION 2 % INJECTION 2 % | GM | |
| LIDOCAINE HCL (CARDIAC) SOLUTION PREFILLED SYRINGE 100 MG/5ML INTRAVENOUS 100 MG/5ML | GM | | lidocaine hcl solution 2 % injection 2 % | GM | |
| lidocaine hcl (pf) injection solution 0.5 %, 1 %, 1.5 %, 2 %, 4 % | GM | | lidocaine hcl urethral/mucosal external gel 2 % | 2 | |
| lidocaine hcl external cream 3 % | 2 | | lidocaine hcl urethral/mucosal external prefilled syringe 2 % | 2 | |
| lidocaine hcl external lotion 3 % | 2 | | LIDOCAINE HCL-TETRACAINE HCL INJECTION SOLUTION 0.4-0.2 % | GM | |
| lidocaine hcl external solution 4 % | 2 | | lidocaine in d5w intravenous solution 4-5 mg/ml-%, 8-5 mg/ml-% | GM | |
| lidocaine hcl injection solution 0.5 % | GM | | LIDOCAINE-EPINEPHRINE (3 ML) INJECTION SOLUTION PREFILLED SYRINGE 0.5 %-1:100000 | GM | |
| | | | lidocaine-epinephrine injection solution 0.5 %-1:200000, 1 %-1:100000, 1.5 %-1:200000, 2 %-1:100000, 2 %-1:200000, 2 %-1:50000 | GM | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------|-----------|-----------------------|-----------------------------------------------------------------------------------------------------------|-----------|-------|
| lidocaine-prilocaine external cream 2.5-2.5 % | 2 | | MARCAINE/EPINEPHRINE INJECTION SOLUTION 0.25% - 1:200000, 0.25-1:200000 %, 0.5% -1:200000, 0.5-1:200000 % | GM | |
| lidocaine-prilocaine external kit 2.5-2.5 % | 2 | | MARCAINE/EPINEPHRINE PF INJECTION SOLUTION 0.25% - 1:200000, 0.5% - 1:200000 | GM | |
| LIDOCAINE-TETRACAINE EXTERNAL CREAM 7-7 % | 4 | | MEDI-DERM/L-RX EXTERNAL CREAM 2-0.035-5-20 % | 4 | |
| LIDODERM EXTERNAL PATCH 5 % | 4 | Brand penalty applies | MEDI-PATCH RX EXTERNAL PATCH 0.5-0.035-5-20 % | 4 | |
| LIDO-EPINEPHRINE-TETRACAINE EXTERNAL SOLUTION 4-0.05-0.5 % | GM | | NAROPIN INJECTION SOLUTION 10 MG/ML, 2 MG/ML, 5 MG/ML, 7.5 MG/ML | GM | |
| lidopin external cream 3 % | 2 | | NESACAINE INJECTION SOLUTION 1 %, 2 % | GM | |
| LIDOPRIL EXTERNAL KIT 2.5-2.5 % | 4 | | NESACAINE-MPF INJECTION SOLUTION 2 %, 3 % | GM | |
| LIDOPRIL XR EXTERNAL KIT 2.5-2.5 % | 4 | | NUMBRINO NASAL SOLUTION 40 MG/ML | GM | |
| LIDOREX EXTERNAL GEL 2.8 % | 4 | | NUVAKAAN EXTERNAL KIT 2.5-2.5 % | 4 | |
| LIDO-SORB EXTERNAL LOTION 3 % | 4 | | ORABLOC INJECTION SOLUTION CARTRIDGE 4 %-1:100000, 4 %-1:200000 | GM | |
| LIVIXIL PAK EXTERNAL KIT 2.5-2.5 % | 4 | | PAINGO KFT EXTERNAL KIT 2.5-2.5-10-30 % | GM | |
| MARCAINE INJECTION SOLUTION 0.25 %, 0.5 %, 0.75 % | GM | | PLIAGLIS EXTERNAL CREAM 7-7 % | 4 | |
| MARCAINE PRESERVATIVE FREE INJECTION SOLUTION 0.25 %, 0.5 % | GM | | polocaine injection solution 1 %, 2 % | GM | |
| MARCAINE SPINAL INTRATHECAL SOLUTION 0.75-8.25 % | GM | | polocaine-mpf injection solution 1 %, 1.5 %, 2 % | GM | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------|-----------|------------------------|--------------------------------------------------------------------------------------------------|-----------|-------|
| POSIMIR INJECTION SOLUTION 660 MG/5ML | GM | | ROPIV-CLONIDINE-KETOROLAC SOLUTION PREFILLED SYRINGE 123-0.04-15 MG/50ML | GM | |
| premium lidocaine external ointment 5 % | 2 | QL (50 GM per 30 days) | SENSORCAINE INJECTION SOLUTION 0.25 %, 0.5 % | GM | |
| PRILOLID EXTERNAL KIT 2.5-2.5 % | 4 | | SENSORCAINE/EPINEPHRINE INJECTION SOLUTION 0.25% - 1:200000, 0.5% - 1:200000 | GM | |
| PROXIVOL EXTERNAL GEL 2 % | 4 | | SENSORCAINE-MPF INJECTION SOLUTION 0.25 %, 0.5 %, 0.75 % | GM | |
| RECK SOLUTION PREFILLED SYRINGE 123-0.25-0.04- 15 MG/50ML | GM | | SENSORCAINE-MPF/EPINEPHRINE INJECTION SOLUTION 0.25% -1:200000, 0.5% - 1:200000, 0.75-1:200000 % | GM | |
| RELADOR PAK EXTERNAL KIT 2.5-2.5 % | 4 | | SYNERA EXTERNAL PATCH 70-70 MG | GM | |
| RELADOR PAK PLUS EXTERNAL KIT 2.5-2.5 % | 4 | | SYNVEXIA TC EXTERNAL CREAM 4-1 % | 4 | |
| RENOVO EXTERNAL PATCH 0.0375-5 % | 4 | | VEXATROL EXTERNAL KIT 2.5-2.5 % | 4 | |
| ROPIVACAINE HCL EPIDURAL SOLUTION 0.2 % | GM | | XARACOLL IMPLANT IMPLANT 3 X 100 MG | GM | |
| ropivacaine hcl injection solution 10 mg/ml, 5 mg/ml, 7.5 mg/ml | GM | | xylocaine dental injection solution 2 %-1:100000, 2 %-1:50000 | GM | |
| ROPIVACAINE HCL INJECTION SOLUTION PREFILLED SYRINGE 0.2 %, 0.5 % | GM | | XYLOCAINE INJECTION SOLUTION 0.5 %, 1 %, 2 % | GM | |
| ropivacaine hcl solution 2 mg/ml injection 2 mg/ml | GM | | XYLOCAINE/EPINEPHRINE INJECTION SOLUTION 0.5 %- 1:200000, 1 %-1:100000, 2 %-1:100000 | GM | |
| ROPIVACAINE HCL SOLUTION 2 MG/ML INJECTION 2 MG/ML | GM | | | | |
| ROPIVACAINE HCL-NACL EPIDURAL SOLUTION 0.2-0.9 % | GM | | | | |
| ROPIVACAINE HCL-NACL INJECTION SOLUTION 0.2-0.9 % | GM | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------------------|-----------|-------|
| XYLOCAINE-MPF INJECTION SOLUTION 0.5 %, 1 %, 1.5 %, 2 % | GM | |
| XYLOCAINE-MPF/EPINEPHRINE INJECTION SOLUTION 1 %-1:200000, 1.5 %-1:200000, 2 %-1:200000 | GM | |
| ZERUVIA EXTERNAL PATCH 4-1 % | 4 | |
| ZINGO INTRADERMAL JET-INJECTOR 0.5 MG | 4 | |
| ZIONODIL 100 EXTERNAL LOTION 3 % | 4 | |
| ZIONODIL EXTERNAL LOTION 3 % | 4 | |
| Anti-Addiction / Substance Abuse Treatment Agents | | |
| acamprosate calcium oral tablet delayed release 333 mg | 1 | |
| APO-VARENICLINE ORAL TABLET 0.5 MG, 1 MG | PV | |
| BUNAVAIL BUCCAL FILM 2.1-0.3 MG, 4.2-0.7 MG, 6.3-1 MG | 3 | |
| buprenorphine hcl sublingual tablet sublingual 2 mg, 8 mg | 1 | |
| buprenorphine hcl-naloxone hcl sublingual film 12-3 mg, 2-0.5 mg, 4-1 mg, 8-2 mg | 1 | |
| buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5 mg, 8-2 mg | 1 | |
| bupropion hcl er (smoking det) oral tablet extended release 12 hour 150 mg | PV | |

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------|-----------|-------------------------|
| CHANTIX CONTINUING MONTH PAK ORAL TABLET 1 MG | PV | |
| CHANTIX ORAL TABLET 0.5 MG, 1 MG | PV | |
| CHANTIX STARTING MONTH PAK ORAL TABLET THERAPY PACK 0.5 MG X 11 & 1 MG X 42 | PV | |
| disulfiram oral tablet 250 mg, 500 mg | 1 | |
| goodsense nicotine mouth/throat lozenge 4 mg | PV | |
| habitrol transdermal patch 24 hour 21 mg/24hr | PV | |
| KLOXXADO NASAL LIQUID 8 MG/0.1ML | 3 | |
| LIFEMS NALOXONE INJECTION PREFILLED SYRINGE KIT 2 MG/2ML | 3 | |
| LUCEMYRA ORAL TABLET 0.18 MG | 3 | QL (224 EA per 14 days) |
| NALMEFENE HCL INJECTION SOLUTION 1 MG/ML | 3 | |
| naloxone hcl injection solution 0.4 mg/ml, 4 mg/10ml | 1 | |
| naloxone hcl injection solution cartridge 0.4 mg/ml | 1 | |
| naloxone hcl injection solution prefilled syringe 2 mg/2ml | 1 | |
| naloxone hcl nasal liquid 4 mg/0.1ml | 1 | |
| naltrexone hcl oral tablet 50 mg | 1 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------------------|-----------|-----------------------|
| NALTREXONE SUBCUTANEOUS IMPLANT 200-6.5 MG | 3 | |
| NARCAN NASAL LIQUID 4 MG/0.1ML | 3 | Brand penalty applies |
| NICORETTE MOUTH/THROAT GUM 2 MG | PV | |
| NICORETTE MOUTH/THROAT LOZENGE 4 MG | PV | |
| nicotine polacrilex mini mouth/throat lozenge 2 mg | PV | |
| nicotine polacrilex mouth/throat gum 2 mg, 4 mg | PV | |
| nicotine polacrilex mouth/throat lozenge 2 mg, 4 mg | PV | |
| nicotine step 1 transdermal patch 24 hour 21 mg/24hr | PV | |
| nicotine step 2 transdermal patch 24 hour 14 mg/24hr | PV | |
| nicotine step 3 transdermal patch 24 hour 7 mg/24hr | PV | |
| nicotine transdermal kit 21-14-7 mg/24hr | PV | |
| NICOTROL INHALATION INHALER 10 MG | PV | |
| NICOTROL NS NASAL SOLUTION 10 MG/ML | PV | |
| SUBLOCADE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.5ML, 300 MG/1.5ML | 3 | |

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------------------------------------------|-----------|------------------------|
| SUBOXONE SUBLINGUAL FILM 12-3 MG, 2-0.5 MG, 4-1 MG, 8-2 MG | 3 | |
| varenicline tartrate oral tablet 0.5 mg, 1 mg | PV | |
| varenicline tartrate oral tablet therapy pack 0.5 mg x 11 & 1 mg x 42 | PV | |
| VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED 380 MG | 3 | |
| ZIMHI INJECTION SOLUTION PREFILLED SYRINGE 5 MG/0.5ML | 3 | |
| ZUBSOLV SUBLINGUAL TABLET SUBLINGUAL 0.7-0.18 MG, 1.4-0.36 MG, 11.4-2.9 MG, 2.9-0.71 MG, 5.7-1.4 MG, 8.6-2.1 MG | 3 | |
| Antibacterials | | |
| AEMCOLO ORAL TABLET DELAYED RELEASE 194 MG | 4 | QL (12 EA per 30 days) |
| ALTABAX EXTERNAL OINTMENT 1 % | 4 | ST |
| amoxicillin oral capsule 250 mg, 500 mg | 2 | |
| amoxicillin oral suspension reconstituted 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml | 1 | |
| amoxicillin oral tablet 500 mg | 2 | |
| amoxicillin oral tablet 875 mg | 1 | |
| amoxicillin oral tablet chewable 125 mg, 250 mg | 2 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|----------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------|-------------------------------------------------------------------|-----------|-----------------------|
| amoxicillin-potassium clavulanate er oral tablet extended release 12 hour 1000-62.5 mg | 2 | | AUGMENTIN ORAL SUSPENSION RECONSTITUTED 125-31.25 MG/5ML | 4 | |
| amoxicillin-potassium clavulanate oral suspension reconstituted 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5ml, 600-42.9 mg/5ml | 2 | | AUGMENTIN ORAL SUSPENSION RECONSTITUTED 250-62.5 MG/5ML | 4 | Brand penalty applies |
| amoxicillin-potassium clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg | 2 | | AUGMENTIN ORAL TABLET 500-125 MG | 4 | Brand penalty applies |
| amoxicillin-potassium clavulanate oral tablet chewable 200-28.5 mg, 400-57 mg | 2 | | avidoxy oral tablet 100 mg | 2 | |
| ampicillin oral capsule 500 mg | 1 | | AVYCAZ INTRAVENOUS SOLUTION RECONSTITUTED 2.5 (2-0.5) GM | GM | |
| ampicillin sodium injection solution reconstituted 1 gm, 125 mg, 2 gm, 250 mg, 500 mg | GM | | AZACTAM INJECTION SOLUTION RECONSTITUTED 1 GM, 2 GM | GM | |
| ampicillin sodium intravenous solution reconstituted 1 gm, 10 gm, 2 gm | GM | | azithromycin intravenous solution reconstituted 500 mg | GM | |
| ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm, 3 (2-1) gm | GM | | azithromycin oral packet 1 gm | 2 | |
| ampicillin-sulbactam sodium intravenous solution reconstituted 15 (10-5) gm | GM | | azithromycin oral suspension reconstituted 100 mg/5ml, 200 mg/5ml | 2 | |
| ARIKAYCE INHALATION SUSPENSION 590 MG/8.4ML | 6 | PA | azithromycin oral tablet 250 mg, 500 mg, 600 mg | 2 | |
| AUGMENTIN ES-600 ORAL SUSPENSION RECONSTITUTED 600-42.9 MG/5ML | 4 | Brand penalty applies | aztreonam injection solution reconstituted 1 gm, 2 gm | GM | |
| | | | baciim intramuscular solution reconstituted 50000 unit | GM | |
| | | | bacitracin intramuscular solution reconstituted 50000 unit | GM | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------------------------------|-----------|-----------------------|---------------------------------------------------------------------------------------------|-----------|-------|
| BACTRIM DS ORAL TABLET 800-160 MG | 4 | Brand penalty applies | cefadroxil oral capsule 500 mg | 2 | |
| BACTRIM ORAL TABLET 400-80 MG | 4 | Brand penalty applies | cefadroxil oral suspension reconstituted 250 mg/5ml, 500 mg/5ml | 2 | |
| BAXDELA INTRAVENOUS SOLUTION RECONSTITUTED 300 MG | 5 | Specialty Medical | cefadroxil oral tablet 1 gm | 2 | |
| BAXDELA ORAL TABLET 450 MG | 5 | | CEFAZOLIN IN SODIUM CHLORIDE INTRAVENOUS SOLUTION 2-0.9 GM/100ML-%, 3-0.9 GM/100ML-% | GM | |
| benzalkonium chloride external solution , 50 % | 2 | | CEFAZOLIN SODIUM INJECTION SOLUTION PREFILLED SYRINGE 3 GM/30ML | GM | |
| BICILLIN C-R 900/300 INTRAMUSCULAR SUSPENSION 900000-300000 UNIT/2ML | GM | | cefazolin sodium injection solution reconstituted 1 gm, 10 gm, 100 gm, 2 gm, 300 gm, 500 mg | GM | |
| BICILLIN C-R INTRAMUSCULAR SUSPENSION 1200000 UNIT/2ML | GM | | CEFAZOLIN SODIUM INTRAVENOUS SOLUTION PREFILLED SYRINGE 1 GM/10ML, 2 GM/20ML | GM | |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION 2400000 UNIT/4ML | GM | | cefazolin sodium intravenous solution reconstituted 1 gm | GM | |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1200000 UNIT/2ML, 600000 UNIT/ML | GM | | cefazolin sodium-dextrose intravenous solution 1-4 gm/50ml-%, 2-4 gm/100ml-% | GM | |
| cefaclor er oral tablet extended release 12 hour 500 mg | 2 | | CEFAZOLIN SODIUM-DEXTROSE INTRAVENOUS SOLUTION 2-5 GM/100ML-% | GM | |
| cefaclor oral capsule 250 mg, 500 mg | 2 | | cefazolin sodium-dextrose intravenous solution reconstituted 1-4 gm-%(50ml), 2-3 gm-%(50ml) | GM | |
| cefaclor oral suspension reconstituted 125 mg/5ml, 250 mg/5ml, 375 mg/5ml | 2 | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------------------------------|-----------|-------|
| cefдинир oral capsule 300 mg | 2 | |
| cefдинир oral suspension reconstituted 125 mg/5ml, 250 mg/5ml | 2 | |
| cefepime hcl injection solution reconstituted 1 gm, 2 gm | GM | |
| cefepime hcl intravenous solution 1 gm/50ml, 2 gm/100ml | GM | |
| cefepime hcl intravenous solution reconstituted 100 gm, 2 gm | GM | |
| cefepime-dextrose intravenous solution reconstituted 1-5 gm-%(50ml), 2-5 gm-%(50ml) | GM | |
| cefixime oral capsule 400 mg | 2 | |
| cefixime oral suspension reconstituted 100 mg/5ml, 200 mg/5ml | 2 | |
| CEFOTAN INJECTION SOLUTION RECONSTITUTED 1 GM, 2 GM | GM | |
| CEFOTAXIME SODIUM INJECTION SOLUTION RECONSTITUTED 1 GM, 2 GM | GM | |
| cefotetan disodium injection solution reconstituted 1 gm, 2 gm | GM | |
| cefotetan disodium-dextrose intravenous solution reconstituted 1-3.58 gm-%(50ml), 2-2.08 gm-%(50ml) | GM | |

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------------------------|-----------|-------|
| cefloxitin sodium intravenous solution reconstituted 1 gm, 10 gm, 2 gm | GM | |
| CEFOXITIN SODIUM-DEXTROSE INTRAVENOUS SOLUTION RECONSTITUTED 1-4 GM-%(50ML), 2-2.2 GM-%(50ML) | GM | |
| cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml | 2 | |
| cefpodoxime proxetil oral tablet 100 mg, 200 mg | 2 | |
| cefprozil oral suspension reconstituted 125 mg/5ml, 250 mg/5ml | 2 | |
| cefprozil oral tablet 250 mg, 500 mg | 2 | |
| ceftazidime and dextrose intravenous solution reconstituted 1-5 gm-%(50ml), 2-5 gm-%(50ml) | GM | |
| ceftazidime injection solution reconstituted 1 gm, 6 gm | GM | |
| ceftazidime intravenous solution reconstituted 2 gm | GM | |
| ceftriaxone sodium in dextrose intravenous solution 20 mg/ml, 40 mg/ml | GM | |
| ceftriaxone sodium injection solution reconstituted 1 gm, 100 gm, 2 gm, 250 mg, 500 mg | GM | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------------------------------|-----------|-----------------------|
| ceftriaxone sodium intravenous solution reconstituted 1 gm, 10 gm, 2 gm | GM | |
| ceftriaxone sodium-dextrose intravenous solution reconstituted 1-3.74 gm-%(50ml), 2-2.22 gm-%(50ml) | GM | |
| cefuroxime axetil oral tablet 250 mg, 500 mg | 2 | |
| cefuroxime sodium injection solution reconstituted 750 mg | GM | |
| cefuroxime sodium intravenous solution reconstituted 1.5 gm | GM | |
| CENTANY AT EXTERNAL KIT 2 % | 3 | |
| cephalexin oral capsule 250 mg, 500 mg | 1 | |
| cephalexin oral capsule 750 mg | 2 | |
| cephalexin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml | 2 | |
| cephalexin oral tablet 250 mg, 500 mg | 2 | |
| chloramphenicol sod succinate intravenous solution reconstituted 1 gm | GM | |
| CIPRO ORAL SUSPENSION RECONSTITUTED 250 MG/5ML (5%), 500 MG/5ML (10%) | 3 | |
| CIPRO ORAL TABLET 250 MG, 500 MG | 4 | Brand penalty applies |
| ciprofloxacin hcl oral tablet 100 mg, 750 mg | 2 | |

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------------------|-----------|-----------------------|
| ciprofloxacin hcl oral tablet 250 mg, 500 mg | 1 | |
| ciprofloxacin in d5w intravenous solution 200 mg/100ml, 400 mg/200ml | GM | |
| clarithromycin er oral tablet extended release 24 hour 500 mg | 2 | |
| clarithromycin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml | 2 | |
| clarithromycin oral tablet 250 mg, 500 mg | 2 | |
| CLEOCIN ORAL CAPSULE 150 MG, 300 MG, 75 MG | 4 | Brand penalty applies |
| CLEOCIN ORAL SOLUTION RECONSTITUTED 75 MG/5ML | 4 | Brand penalty applies |
| CLEOCIN PHOSPHATE INJECTION SOLUTION 300 MG/2ML, 600 MG/4ML, 9 GM/60ML, 900 MG/6ML | GM | |
| CLEOCIN VAGINAL CREAM 2 % | 4 | Brand penalty applies |
| CLEOCIN VAGINAL SUPPOSITORY 100 MG | 3 | |
| clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg | 2 | |
| clindamycin palmitate hcl oral solution reconstituted 75 mg/5ml | 2 | |
| clindamycin phosphate in d5w intravenous solution 300 mg/50ml, 600 mg/50ml, 900 mg/50ml | GM | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------------------------------------------|-----------|-------------------|-----------------------------------------------------------------------|-----------|-----------------------|
| clindamycin phosphate injection solution 300 mg/2ml, 600 mg/4ml, 9 gm/60ml, 900 mg/6ml, 9000 mg/60ml | GM | | DIFICID ORAL TABLET 200 MG | 5 | |
| clindamycin phosphate vaginal cream 2 % | 2 | | doxy 100 intravenous solution reconstituted 100 mg | GM | |
| CLINDESSE VAGINAL CREAM 2 % | 4 | | doxycycline hyclate intravenous solution reconstituted 100 mg | GM | |
| colistimethate sodium (cba) injection solution reconstituted 150 mg | GM | | doxycycline hyclate oral capsule 100 mg, 50 mg | 2 | |
| COLY-MYCIN M INJECTION SOLUTION RECONSTITUTED 150 MG | GM | | doxycycline hyclate oral tablet 100 mg, 20 mg | 2 | |
| CUBICIN INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | GM | | doxycycline hyclate oral tablet delayed release 100 mg, 150 mg, 75 mg | 2 | |
| CUBICIN RF INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | GM | | doxycycline monohydrate oral capsule 100 mg, 150 mg, 50 mg, 75 mg | 2 | |
| DALVANCE INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | 6 | Specialty Medical | doxycycline monohydrate oral suspension reconstituted 25 mg/5ml | 2 | |
| daptomycin intravenous solution reconstituted 350 mg, 500 mg | GM | | doxycycline monohydrate oral tablet 100 mg, 150 mg, 50 mg, 75 mg | 2 | |
| demeclocycline hcl oral tablet 150 mg, 300 mg | 2 | | E.E.S. 400 ORAL TABLET 400 MG | 4 | |
| dicloxacillin sodium oral capsule 250 mg, 500 mg | 2 | | E.E.S. GRANULES ORAL SUSPENSION RECONSTITUTED 200 MG/5ML | 4 | Brand penalty applies |
| DIFICID ORAL SUSPENSION RECONSTITUTED 40 MG/ML | 5 | | ERYPED 200 ORAL SUSPENSION RECONSTITUTED 200 MG/5ML | 4 | Brand penalty applies |
| | | | ERYPED 400 ORAL SUSPENSION RECONSTITUTED 400 MG/5ML | 4 | Brand penalty applies |
| | | | ERY-TAB ORAL TABLET DELAYED RELEASE 250 MG, 333 MG, 500 MG | 4 | Brand penalty applies |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|----------------------------------------------------------------------------------|-----------|-----------------------|
| ERYTHROCIN LACTOBIONATE INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | GM | |
| ERYTHROCIN STEARATE ORAL TABLET 250 MG | 4 | |
| erythromycin base oral capsule delayed release particles 250 mg | 2 | |
| erythromycin base oral tablet 250 mg, 500 mg | 2 | |
| erythromycin base oral tablet delayed release 250 mg, 333 mg, 500 mg | 2 | |
| erythromycin ethylsuccinate oral suspension reconstituted 200 mg/5ml, 400 mg/5ml | 2 | |
| erythromycin ethylsuccinate oral tablet 400 mg | 2 | |
| erythromycin lactobionate intravenous solution reconstituted 500 mg | GM | |
| erythromycin oral tablet delayed release 250 mg, 333 mg, 500 mg | 2 | |
| FETROJA INTRAVENOUS SOLUTION RECONSTITUTED 1 GM | 6 | Specialty Medical |
| FIRVANQ ORAL SOLUTION RECONSTITUTED 25 MG/ML, 50 MG/ML | 4 | |
| FLAGYL ORAL CAPSULE 375 MG | 4 | Brand penalty applies |

| Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------|
| FLAGYL ORAL TABLET 500 MG | 4 | Brand penalty applies |
| FORTAZ INJECTION SOLUTION RECONSTITUTED 1 GM, 500 MG | GM | |
| FORTAZ INTRAVENOUS SOLUTION RECONSTITUTED 2 GM | GM | |
| fosfomycin tromethamine oral packet 3 gm | 2 | |
| gentamicin in saline intravenous solution 0.8-0.9 mg/ml-%, 1-0.9 mg/ml-%, 1.2-0.9 mg/ml-%, 1.6-0.9 mg/ml-%, 2-0.9 mg/ml-% | GM | |
| gentamicin sulfate external cream 0.1 % | 2 | |
| gentamicin sulfate external ointment 0.1 % | 2 | |
| gentamicin sulfate injection solution 10 mg/ml, 40 mg/ml | GM | |
| HIPREX ORAL TABLET 1 GM | 4 | Brand penalty applies |
| HUMATIN ORAL CAPSULE 250 MG | 4 | Brand penalty applies |
| hydrogen peroxide solution 30 % | 2 | |
| imipenem-cilastatin intravenous solution reconstituted 250 mg, 500 mg | GM | |
| iodine tincture external tincture 2 % | 2 | |
| KEFLEX ORAL CAPSULE 250 MG, 500 MG, 750 MG | 4 | Brand penalty applies |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------------------------------|-----------|-------------------------------|----------------------------------------------------------------------------------------------------|-----------|-------|
| KIMYRSA INTRAVENOUS SOLUTION RECONSTITUTED 1200 MG | 6 | Specialty Medical | mafenide acetate external packet 5 % | 2 | |
| levofloxacin in d5w intravenous solution 250 mg/50ml, 500 mg/100ml, 750 mg/150ml | GM | | meropenem intravenous solution reconstituted 1 gm, 500 mg | GM | |
| levofloxacin intravenous solution 25 mg/ml | GM | | MEROPENEM-SODIUM CHLORIDE INTRAVENOUS SOLUTION RECONSTITUTED 1 GM/50ML, 500 MG/50ML | GM | |
| levofloxacin oral solution 25 mg/ml | 2 | | MERREM INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | GM | |
| levofloxacin oral tablet 250 mg, 500 mg, 750 mg | 2 | | methenamine hippurate oral tablet 1 gm | 2 | |
| LINCOCIN INJECTION SOLUTION 300 MG/ML | GM | | methenamine mandelate oral tablet 0.5 gm, 1 gm | 2 | |
| lincomycin hcl injection solution 300 mg/ml | GM | | metronidazole intravenous solution 500 mg/100ml | GM | |
| linezolid in sodium chloride intravenous solution 600-0.9 mg/300ml-% | 5 | Specialty Medical | metronidazole oral capsule 375 mg | 2 | |
| linezolid intravenous solution 600 mg/300ml | 5 | Specialty Medical | metronidazole oral tablet 250 mg, 500 mg | 2 | |
| linezolid oral suspension reconstituted 100 mg/5ml | 5 | QL (900 ML per 30 days) | metronidazole vaginal gel 0.75 % | 2 | |
| linezolid oral tablet 600 mg | 5 | QL (60 EA per 30 days) | MINOCIN INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | GM | |
| LUGOLS STRONG IODINE EXTERNAL SOLUTION 5-10 % | 4 | | minocycline hcl oral capsule 100 mg, 50 mg, 75 mg | 2 | |
| LYMEPAK ORAL TABLET 100 MG | 4 | | minocycline hcl oral tablet 100 mg, 50 mg, 75 mg | 2 | |
| MACROBID ORAL CAPSULE 100 MG | 4 | Brand penalty applies | mondoxyne nl oral capsule 100 mg, 75 mg | 2 | |
| MACRODANTIN ORAL CAPSULE 100 MG, 25 MG, 50 MG | 4 | Brand penalty applies | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------------|-----------|-----------------------|
| MONUROL ORAL PACKET 3 GM | 4 | Brand penalty applies |
| morgidox oral capsule 100 mg | 2 | |
| moxifloxacin hcl in nacl intravenous solution 400 mg/250ml | GM | |
| MOXIFLOXACIN HCL INTRAVENOUS SOLUTION 400 MG/250ML | GM | |
| moxifloxacin hcl oral tablet 400 mg | 2 | |
| mupirocin external ointment 2 % | 2 | |
| NAFCILLIN SODIUM IN DEXTROSE INTRAVENOUS SOLUTION 1 GM/50ML, 2 GM/100ML | GM | |
| nafcillin sodium injection solution reconstituted 1 gm, 2 gm | GM | |
| nafcillin sodium intravenous solution reconstituted 1 gm, 10 gm, 2 gm | GM | |
| neomycin sulfate oral tablet 500 mg | 2 | |
| neomycin-polymyxin b gu irrigation solution 40-200000 | 2 | |
| nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg | 2 | |
| nitrofurantoin monohydrate macrocrystals oral capsule 100 mg | 2 | |
| nitrofurantoin oral suspension 25 mg/5ml | 2 | |

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------------------------|-----------|------------------------|
| NUTRIDOX ORAL KIT 75 MG | 4 | |
| NUZYRA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 6 | Specialty Medical |
| NUZYRA ORAL TABLET 150 MG | 6 | QL (30 EA per 14 days) |
| ofloxacin oral tablet 300 mg, 400 mg | 2 | |
| ORBACTIV INTRAVENOUS SOLUTION RECONSTITUTED 400 MG | 5 | Specialty Medical |
| OXACILLIN SODIUM IN DEXTROSE INTRAVENOUS SOLUTION 1 GM/50ML, 2 GM/50ML | GM | |
| oxacillin sodium injection solution reconstituted 1 gm, 2 gm | GM | |
| oxacillin sodium intravenous solution reconstituted 10 gm | GM | |
| paromomycin sulfate oral capsule 250 mg | 2 | |
| PENICILLIN G POT IN DEXTROSE INTRAVENOUS SOLUTION 20000 UNIT/ML, 40000 UNIT/ML, 60000 UNIT/ML | GM | |
| penicillin g potassium injection solution reconstituted 20000000 unit, 5000000 unit | GM | |
| penicillin g procaine intramuscular suspension 600000 unit/ml | GM | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------|------------------------------------------------------------------|-----------|-----------------------|
| penicillin g sodium injection solution reconstituted 5000000 unit | GM | | silver nitrate external solution 0.5 %, 10 %, 25 %, 50 % | 2 | |
| penicillin v potassium oral solution reconstituted 125 mg/5ml, 250 mg/5ml | 2 | | silver sulfadiazine external cream 1 % | 2 | |
| penicillin v potassium oral tablet 250 mg, 500 mg | 1 | | SIVEXTRO INTRAVENOUS SOLUTION RECONSTITUTED 200 MG | 6 | Specialty Medical |
| PFIZERPEN INJECTION SOLUTION RECONSTITUTED 20000000 UNIT, 5000000 UNIT | GM | | SIVEXTRO ORAL TABLET 200 MG | 6 | QL (6 EA per 30 days) |
| piperacillin sod-tazobactam so intravenous solution reconstituted 13.5 (12-1.5) gm, 2.25 (2-0.25) gm, 3-0.375 gm, 3.375 (3-0.375) gm, 4-0.5 gm, 4.5 (4-0.5) gm, 40.5 (36-4.5) gm | GM | | SOLOSEC ORAL PACKET 2 GM | 4 | |
| polymyxin b sulfate injection solution reconstituted 500000 unit | GM | | ssd external cream 1 % | 2 | |
| PRIMAXIN IV INTRAVENOUS SOLUTION RECONSTITUTED 500-500 MG | GM | | streptomycin sulfate intramuscular solution reconstituted 1 gm | GM | |
| PRIMSOL ORAL SOLUTION 50 MG/5ML | 4 | | sulfadiazine oral tablet 500 mg | 2 | |
| RECARBRIO INTRAVENOUS SOLUTION RECONSTITUTED 1.25 GM | 6 | Specialty Medical | sulfamethoxazole-trimethoprim intravenous solution 400-80 mg/5ml | GM | |
| SILVADENE EXTERNAL CREAM 1 % | 4 | Brand penalty applies | sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5ml | 2 | |
| | | | sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg | 1 | |
| | | | SULFAMYLON EXTERNAL CREAM 85 MG/GM | 4 | |
| | | | SULFAMYLON EXTERNAL PACKET 5 % | 4 | Brand penalty applies |
| | | | sulfatrim pediatric oral suspension 200-40 mg/5ml | 2 | |
| | | | SUPRAX ORAL CAPSULE 400 MG | 4 | Brand penalty applies |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------------|-----------|-----------------------|----------------------------------------------------------------------------------------------------|-----------|-----------------------|
| SUPRAX ORAL SUSPENSION RECONSTITUTED 100 MG/5ML, 200 MG/5ML | 4 | Brand penalty applies | trimethoprim oral tablet 100 mg | 2 | |
| SUPRAX ORAL SUSPENSION RECONSTITUTED 500 MG/5ML | 4 | | TYGACIL INTRAVENOUS SOLUTION RECONSTITUTED 50 MG | GM | |
| SUPRAX ORAL TABLET CHEWABLE 100 MG, 200 MG | 4 | | UNASYN INJECTION SOLUTION RECONSTITUTED 1.5 (1-0.5) GM, 3 (2-1) GM | GM | |
| SYNERCID INTRAVENOUS SOLUTION RECONSTITUTED 150-350 MG | GM | | UNASYN INTRAVENOUS SOLUTION RECONSTITUTED 15 (10-5) GM | GM | |
| tazicef injection solution reconstituted 1 gm | GM | | VABOMERE INTRAVENOUS SOLUTION RECONSTITUTED 2 (1-1) GM | GM | |
| TAZICEF INTRAVENOUS SOLUTION 1 GM/50ML | GM | | VANCOGIN ORAL CAPSULE 125 MG, 250 MG | 4 | Brand penalty applies |
| tazicef intravenous solution reconstituted 1 gm, 2 gm, 6 gm | GM | | VANCOMYCIN HCL IN DEXTROSE INTRAVENOUS SOLUTION 1.25-5 GM/250ML-%, 1.5-5 GM/250ML-% | GM | |
| TEFLARO INTRAVENOUS SOLUTION RECONSTITUTED 400 MG, 600 MG | GM | | vancomycin hcl in dextrose intravenous solution 1-5 gm/200ml-%, 500-5 mg/100ml-%, 750-5 mg/150ml-% | GM | |
| tetracycline hcl oral capsule 250 mg, 500 mg | 2 | | vancomycin hcl in nacl intravenous solution 1-0.9 gm/200ml-%, 500-0.9 mg/100ml-% | GM | |
| tigecycline intravenous solution reconstituted 50 mg | GM | | | | |
| tinidazole oral tablet 250 mg, 500 mg | 2 | | | | |
| tobramycin sulfate injection solution 1.2 gm/30ml, 10 mg/ml, 2 gm/50ml, 80 mg/2ml | GM | | | | |
| tobramycin sulfate injection solution reconstituted 1.2 gm | GM | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------|
| VANCOMYCIN HCL IN NACL INTRAVENOUS SOLUTION 1-0.9 GM/250ML-%, 1.25-0.9 GM/250ML-%, 1.5-0.9 GM/250ML-%, 1.5-0.9 GM/500ML-%, 1.75-0.9 GM/250ML-%, 2-0.9 GM/500ML-% | GM | |
| VANCOMYCIN HCL IN NACL SOLUTION 750-0.9 MG/150ML-% INTRAVENOUS 750-0.9 MG/150ML-% | GM | |
| vancomycin hcl in nacl solution 750-0.9 mg/150ml-% intravenous 750-0.9 mg/150ml-% | GM | |
| vancomycin hcl intravenous solution 1000 mg/200ml, 1500 mg/300ml, 2000 mg/400ml, 500 mg/100ml | GM | |
| vancomycin hcl intravenous solution 1250 mg/250ml, 1750 mg/350ml, 750 mg/150ml | GM | PA |
| vancomycin hcl intravenous solution reconstituted 1 gm, 1.25 gm, 1.5 gm, 10 gm, 5 gm, 500 mg, 750 mg | GM | |
| vancomycin hcl oral capsule 125 mg, 250 mg | 2 | |
| vancomycin hcl oral solution reconstituted 250 mg/5ml | 2 | |
| vandazole vaginal gel 0.75 % | 2 | |
| VIBATIV INTRAVENOUS SOLUTION RECONSTITUTED 750 MG | GM | |

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------|-----------|-----------------------|
| VIBRAMYCIN ORAL CAPSULE 100 MG | 4 | Brand penalty applies |
| VIBRAMYCIN ORAL SUSPENSION RECONSTITUTED 25 MG/5ML | 4 | Brand penalty applies |
| VIBRAMYCIN ORAL SYRUP 50 MG/5ML | 3 | |
| XENLETA INTRAVENOUS SOLUTION 150 MG/15ML | 6 | Specialty Medical |
| XENLETA ORAL TABLET 600 MG | 6 | |
| XEPI EXTERNAL CREAM 1 % | 4 | ST |
| XERAVA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 50 MG | 5 | Specialty Medical |
| XIFAXAN ORAL TABLET 200 MG, 550 MG | 5 | PA |
| ZEMDRI INTRAVENOUS SOLUTION 500 MG/10ML | 6 | Specialty Medical |
| ZERBAXA INTRAVENOUS SOLUTION RECONSTITUTED 1.5 (1-0.5) GM | GM | |
| ZITHROMAX INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | GM | |
| ZITHROMAX ORAL PACKET 1 GM | 4 | Brand penalty applies |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|----------------------------------------------------------------------------|-----------|-------------------------|-----------------------------------------------------------------------------------|-----------|-----------------------|
| ZITHROMAX ORAL SUSPENSION RECONSTITUTED 100 MG/5ML, 200 MG/5ML | 4 | Brand penalty applies | ANGIOMAX INTRAVENOUS SOLUTION RECONSTITUTED 250 MG | GM | |
| ZITHROMAX ORAL TABLET 250 MG, 500 MG | 4 | Brand penalty applies | anticoagulant cit dext soln a in vitro solution 0.8-2.45-2.2 gm/100ml | 2 | |
| ZITHROMAX TRI-PAK ORAL TABLET 500 MG | 4 | Brand penalty applies | ANTICOAGULANT SODIUM CITRATE IN VITRO SOLUTION 4 %, 4 GM/100ML | 4 | |
| ZITHROMAX Z-PAK ORAL TABLET 250 MG | 4 | Brand penalty applies | argatroban in sodium chloride intravenous solution 50-0.9 mg/50ml-% | GM | |
| ZOSYN INTRAVENOUS SOLUTION 2-0.25 GM/50ML, 3-0.375 GM/50ML, 4-0.5 GM/100ML | GM | | argatroban intravenous solution 250 mg/2.5ml, 50 mg/50ml | GM | |
| ZYVOX INTRAVENOUS SOLUTION 200 MG/100ML, 600 MG/300ML | 5 | Specialty Medical | ARIXTRA SUBCUTANEOUS SOLUTION 10 MG/0.8ML, 2.5 MG/0.5ML, 5 MG/0.4ML, 7.5 MG/0.6ML | 4 | Brand penalty applies |
| ZYVOX ORAL SUSPENSION RECONSTITUTED 100 MG/5ML | 5 | QL (900 ML per 30 days) | BIVALIRUDIN RTU INTRAVENOUS SOLUTION 250 MG/50ML | GM | |
| ZYVOX ORAL TABLET 600 MG | 5 | QL (60 EA per 30 days) | bivalirudin trifluoroacetate intravenous solution reconstituted 250 mg | GM | |
| Anticoagulants | | | CATHFLO ACTIVASE INJECTION SOLUTION RECONSTITUTED 2 MG | GM | |
| ACD FORMULA A IN VITRO SOLUTION 0.73-2.45-2.2 GM/100ML | 4 | | dabigatran etexilate mesylate oral capsule 150 mg, 75 mg | 2 | |
| ACD-A NOCLOT-50 IN VITRO SOLUTION 0.73-2.45-2.2 GM/100ML | 4 | | ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK 5 MG | 3 | |
| ACTIVASE INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 50 MG | GM | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------|-------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------|
| ELIQUIS ORAL TABLET 2.5 MG, 5 MG | 3 | | HEPARIN (PORCINE) IN NACL INTRAVENOUS SOLUTION PREFILLED SYRINGE 50-0.9 UNT/50ML-% | GM | |
| enoxaparin sodium injection solution 300 mg/3ml | 2 | | heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 20000 unit/ml, 5000 unit/ml | 2 | |
| enoxaparin sodium injection solution prefilled syringe 100 mg/ml, 120 mg/0.8ml, 150 mg/ml, 30 mg/0.3ml, 40 mg/0.4ml, 60 mg/0.6ml, 80 mg/0.8ml | 2 | | heparin sodium (porcine) injection solution prefilled syringe 5000 unit/0.5ml | GM | |
| fondaparinux sodium subcutaneous solution 10 mg/0.8ml, 2.5 mg/0.5ml, 5 mg/0.4ml, 7.5 mg/0.6ml | 2 | | heparin sodium (porcine) pf injection solution 5000 unit/0.5ml | 2 | |
| FRAGMIN INJECTION INJECTABLE 2500 UNIT/ML | 3 | | heparin sodium (porcine) pf injection solution 5000 unit/ml | GM | |
| FRAGMIN SUBCUTANEOUS SOLUTION 95000 UNIT/3.8ML | 3 | | jantoven oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg | 1 | |
| FRAGMIN SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10000 UNIT/ML, 12500 UNIT/0.5ML, 15000 UNIT/0.6ML, 18000 UNT/0.72ML, 2500 UNIT/0.2ML, 5000 UNIT/0.2ML, 7500 UNIT/0.3ML | 3 | | LOVENOX INJECTION SOLUTION 300 MG/3ML | 4 | Brand penalty applies |
| HEPARIN (PORCINE) IN NACL INTRAVENOUS SOLUTION 2500-0.9 UT/500ML-%, 500-0.9 UT/500ML-%, 5000-0.9 UNIT/L-%, 5000-0.9 UT/500ML-% | GM | | LOVENOX INJECTION SOLUTION PREFILLED SYRINGE 100 MG/ML, 120 MG/0.8ML, 150 MG/ML, 30 MG/0.3ML, 40 MG/0.4ML, 60 MG/0.6ML, 80 MG/0.8ML | 4 | Brand penalty applies |
| heparin (porcine) in nacl intravenous solution 25000-0.45 ut/500ml-% | GM | | PRADAXA ORAL CAPSULE 110 MG, 150 MG, 75 MG | 3 | |
| | | | REGIOCIT EXTRACORPOREAL SOLUTION 0.529 % | GM | |
| | | | SAVAYSA ORAL TABLET 15 MG, 30 MG, 60 MG | 4 | ST |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------------------------|-----------|-------------------|
| SODIUM CITRATE IN VITRO SOLUTION PREFILLED SYRINGE 4 % | GM | |
| SODIUM CITRATE LOCK FLUSH INTRAVENOUS SOLUTION 4 % | GM | |
| SODIUM CITRATE LOCK FLUSH INTRAVENOUS SOLUTION PREFILLED SYRINGE 120 MG/3ML | GM | |
| SODIUM CITRATE-GENTAMICIN SULF INTRAVENOUS SOLUTION 4-320 %-MCG/ML | GM | |
| THROMBATE III INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 500 UNIT | GM | PA |
| TNKASE INTRAVENOUS KIT 50 MG | GM | |
| TRICITRASOL IN VITRO CONCENTRATE 46.7 % | 4 | |
| warfarin sodium oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg | 1 | |
| XARELTO ORAL SUSPENSION RECONSTITUTED 1 MG/ML | 4 | AL (Max 17 Years) |
| XARELTO ORAL TABLET 10 MG, 15 MG, 2.5 MG, 20 MG | 3 | |
| XARELTO STARTER PACK ORAL TABLET THERAPY PACK 15 & 20 MG | 3 | |

| Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------------------|-----------|-------|
| Anticonvulsants - Drugs for Seizures | | |
| APTiom ORAL TABLET 200 MG, 400 MG, 600 MG, 800 MG | 4 | ST |
| BANZEL ORAL SUSPENSION 40 MG/ML | 4 | |
| BANZEL ORAL TABLET 200 MG, 400 MG | 4 | |
| BRIVIACT INTRAVENOUS SOLUTION 50 MG/5ML | GM | ST |
| BRIVIACT ORAL SOLUTION 10 MG/ML | 4 | ST |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | 4 | ST |
| carbamazepine er oral capsule extended release 12 hour 100 mg, 200 mg, 300 mg | 2 | |
| carbamazepine er oral tablet extended release 12 hour 100 mg, 200 mg, 400 mg | 2 | |
| carbamazepine oral suspension 100 mg/5ml | 2 | |
| carbamazepine oral tablet 200 mg | 2 | |
| carbamazepine oral tablet chewable 100 mg | 2 | |
| CARBATROL ORAL CAPSULE EXTENDED RELEASE 12 HOUR 100 MG, 200 MG, 300 MG | 4 | |
| CELONTIN ORAL CAPSULE 300 MG | 4 | |
| CEREBYX INJECTION SOLUTION 100 MG PE/2ML, 500 MG PE/10ML | GM | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------------------|-----------|-------|----------------------------------------------------------------------|-----------|-------|
| clobazam oral suspension 2.5 mg/ml | 2 | | divalproex sodium oral capsule delayed release sprinkle 125 mg | 2 | |
| clobazam oral tablet 10 mg, 20 mg | 2 | | divalproex sodium oral tablet delayed release 125 mg, 250 mg, 500 mg | 2 | |
| DEPAKOTE ER ORAL TABLET EXTENDED RELEASE 24 HOUR 250 MG, 500 MG | 4 | | EPIDIOLEX ORAL SOLUTION 100 MG/ML | 6 | PA |
| DEPAKOTE ORAL TABLET DELAYED RELEASE 125 MG, 250 MG, 500 MG | 4 | | epitol oral tablet 200 mg | 2 | |
| DEPAKOTE SPRINKLES ORAL CAPSULE DELAYED RELEASE SPRINKLE 125 MG | 4 | | EPRONTIA ORAL SOLUTION 25 MG/ML | 4 | |
| DIACOMIT ORAL CAPSULE 250 MG, 500 MG | 4 | | ethosuximide oral capsule 250 mg | 2 | |
| DIACOMIT ORAL PACKET 250 MG, 500 MG | 4 | | ethosuximide oral solution 250 mg/5ml | 2 | |
| DIASTAT ACUDIAL RECTAL GEL 10 MG, 20 MG | 4 | | felbamate oral suspension 600 mg/5ml | 2 | |
| DIASTAT PEDIATRIC RECTAL GEL 2.5 MG | 4 | | felbamate oral tablet 400 mg, 600 mg | 2 | |
| diazepam rectal gel 10 mg, 2.5 mg, 20 mg | 2 | | FELBATOL ORAL SUSPENSION 600 MG/5ML | 4 | |
| DILANTIN INFATABS ORAL TABLET CHEWABLE 50 MG | 3 | | FELBATOL ORAL TABLET 400 MG, 600 MG | 4 | |
| DILANTIN ORAL CAPSULE 100 MG, 30 MG | 3 | | FINTEPLA ORAL SOLUTION 2.2 MG/ML | 6 | PA |
| DILANTIN ORAL SUSPENSION 125 MG/5ML | 4 | | fosphenytoin sodium injection solution 100 mg pe/2ml, 500 mg pe/10ml | GM | |
| divalproex sodium er oral tablet extended release 24 hour 250 mg, 500 mg | 2 | | FYCOMPA ORAL SUSPENSION 0.5 MG/ML | 4 | |
| | | | FYCOMPA ORAL TABLET 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 4 | |
| | | | gabapentin oral capsule 100 mg, 300 mg, 400 mg | 2 | |
| | | | gabapentin oral solution 250 mg/5ml, 300 mg/6ml | 2 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|----------------------------------------------------------------------------------------|-----------|-------|--------------------------------------------------------------------------------------------------|-----------|-------|
| GABAPENTIN ORAL TABLET 25 MG, 50 MG | 3 | | LAMICTAL STARTER ORAL KIT 35 X 25 MG, 42 X 25 MG & 7 X 100 MG, 84 X 25 MG & 14X100 MG | 4 | |
| gabapentin oral tablet 600 mg, 800 mg | 2 | | LAMICTAL XR ORAL KIT 21 X 25 MG & 7 X 50 MG, 25 & 50 & 100 MG, 50 & 100 & 200 MG | 4 | |
| GABITRIL ORAL TABLET 12 MG, 16 MG, 2 MG, 4 MG | 4 | | LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100 MG, 200 MG, 25 MG, 250 MG, 300 MG, 50 MG | 4 | |
| KEPPRA INTRAVENOUS SOLUTION 500 MG/5ML | GM | | lamotrigine er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg | 2 | |
| KEPPRA ORAL SOLUTION 100 MG/ML | 4 | | lamotrigine oral kit 25 & 50 & 100 mg | 2 | |
| KEPPRA ORAL TABLET 1000 MG, 250 MG, 500 MG, 750 MG | 4 | | lamotrigine oral tablet 100 mg, 150 mg, 200 mg | 1 | |
| KEPPRA XR ORAL TABLET EXTENDED RELEASE 24 HOUR 500 MG, 750 MG | 4 | | lamotrigine oral tablet 25 mg | 2 | |
| lacosamide intravenous solution 200 mg/20ml | GM | | lamotrigine oral tablet chewable 25 mg, 5 mg | 2 | |
| lacosamide oral solution 10 mg/ml | 2 | | lamotrigine oral tablet dispersible 100 mg, 200 mg, 25 mg, 50 mg | 2 | |
| lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg | 2 | | lamotrigine starter kit-blue oral kit 35 x 25 mg | 2 | |
| LAMICTAL ODT ORAL KIT 21 X 25 MG & 7 X 50 MG, 25 & 50 & 100 MG, 42 X 50 MG & 14X100 MG | 4 | | lamotrigine starter kit-green oral kit 84 x 25 mg & 14x100 mg | 2 | |
| LAMICTAL ODT ORAL TABLET DISPERSIBLE 100 MG, 200 MG, 25 MG, 50 MG | 4 | | lamotrigine starter kit-orange oral kit 42 x 25 mg & 7 x 100 mg | 2 | |
| LAMICTAL ORAL TABLET 100 MG, 150 MG, 200 MG, 25 MG | 4 | | levetiracetam er oral tablet extended release 24 hour 500 mg, 750 mg | 2 | |
| LAMICTAL ORAL TABLET CHEWABLE 25 MG, 5 MG | 4 | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------------------------|-----------|------------------------|-------------------------------------------------------------------------------------------|-----------|-------|
| levetiracetam in nacl intravenous solution 1000 mg/100ml, 1500 mg/100ml, 500 mg/100ml | GM | | pentobarbital sodium injection solution 50 mg/ml | GM | |
| levetiracetam intravenous solution 500 mg/5ml | GM | | phenobarbital oral elixir 20 mg/5ml | 2 | |
| levetiracetam oral solution 100 mg/ml | 2 | | phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg | 2 | |
| levetiracetam oral tablet 1000 mg, 250 mg, 500 mg, 750 mg | 2 | | phenobarbital sodium injection solution 130 mg/ml, 65 mg/ml | GM | |
| MYSOLINE ORAL TABLET 250 MG, 50 MG | 4 | | PHENYTEK ORAL CAPSULE 200 MG, 300 MG | 4 | |
| NAYZILAM NASAL SOLUTION 5 MG/0.1ML | 4 | QL (10 EA per 30 days) | phenytoin infatabs oral tablet chewable 50 mg | 2 | |
| NEMBUTAL INJECTION SOLUTION 50 MG/ML | GM | | phenytoin oral suspension 100 mg/4ml, 125 mg/5ml | 2 | |
| NEURONTIN ORAL CAPSULE 100 MG, 300 MG, 400 MG | 4 | | phenytoin oral tablet chewable 50 mg | 2 | |
| NEURONTIN ORAL SOLUTION 250 MG/5ML | 4 | | phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg | 2 | |
| NEURONTIN ORAL TABLET 600 MG, 800 MG | 4 | | phenytoin sodium injection solution 50 mg/ml | GM | |
| ONFI ORAL SUSPENSION 2.5 MG/ML | 4 | | primidone oral tablet 250 mg, 50 mg | 2 | |
| ONFI ORAL TABLET 10 MG, 20 MG | 4 | | QUDEXY XR ORAL CAPSULE ER 24 HOUR SPRINKLE 100 MG, 150 MG, 200 MG, 25 MG, 50 MG | 4 | PA |
| oxcarbazepine oral suspension 300 mg/5ml | 2 | | roweepra oral tablet 500 mg | 2 | |
| oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg | 2 | | rufinamide oral suspension 40 mg/ml | 2 | |
| OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HOUR 150 MG, 300 MG, 600 MG | 4 | | rufinamide oral tablet 200 mg, 400 mg | 2 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|----------------------------------------------------------------------------|-----------|-------|-------------------------------------------------------------------------------------|-----------|-------|
| SABRIL ORAL PACKET 500 MG | 6 | PA | topiramate er oral capsule er 24 hour sprinkle 100 mg, 150 mg, 200 mg, 25 mg, 50 mg | 2 | PA |
| SABRIL ORAL TABLET 500 MG | 6 | PA | topiramate oral capsule sprinkle 15 mg, 25 mg | 2 | |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 1000 MG, 250 MG, 500 MG, 750 MG | 4 | ST | topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg | 2 | |
| subvenite oral tablet 100 mg, 150 mg, 200 mg | 1 | | TRILEPTAL ORAL SUSPENSION 300 MG/5ML | 4 | |
| subvenite oral tablet 25 mg | 2 | | TRILEPTAL ORAL TABLET 150 MG, 300 MG, 600 MG | 4 | |
| subvenite starter kit-blue oral kit 35 x 25 mg | 2 | | TROKENDI XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 100 MG, 200 MG, 25 MG, 50 MG | 4 | PA |
| subvenite starter kit-green oral kit 84 x 25 mg & 14x100 mg | 2 | | valproate sodium intravenous solution 100 mg/ml | GM | |
| subvenite starter kit-orange oral kit 42 x 25 mg & 7 x 100 mg | 2 | | valproic acid oral capsule 250 mg | 2 | |
| SYMPAZAN ORAL FILM 10 MG, 20 MG, 5 MG | 4 | | valproic acid oral solution 250 mg/5ml | 2 | |
| TEGRETOL ORAL SUSPENSION 100 MG/5ML | 4 | | VALTOCO NASAL LIQUID 10 MG/0.1ML, 5 MG/0.1ML | 4 | |
| TEGRETOL ORAL TABLET 200 MG | 4 | | VALTOCO NASAL LIQUID THERAPY PACK 10 MG/0.1ML, 7.5 MG/0.1ML | 4 | |
| TEGRETOL-XR ORAL TABLET EXTENDED RELEASE 12 HOUR 100 MG, 200 MG, 400 MG | 4 | | vigabatrin oral packet 500 mg | 5 | PA |
| tiagabine hcl oral tablet 12 mg, 16 mg, 2 mg, 4 mg | 2 | | vigabatrin oral tablet 500 mg | 5 | PA |
| TOPAMAX ORAL TABLET 100 MG, 200 MG, 25 MG, 50 MG | 4 | | vigadrone oral packet 500 mg | 5 | PA |
| TOPAMAX SPRINKLE ORAL CAPSULE SPRINKLE 15 MG, 25 MG | 4 | | VIMPAT INTRAVENOUS SOLUTION 200 MG/20ML | GM | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------|--------------------------------------------------------------------------------------|-----------|-----------------------|
| VIMPAT ORAL SOLUTION 10 MG/ML | 4 | | donepezil hcl oral tablet dispersible 10 mg, 5 mg | 2 | |
| VIMPAT ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 4 | | EXELON TRANSDERMAL PATCH 24 HOUR 13.3 MG/24HR, 4.6 MG/24HR, 9.5 MG/24HR | 4 | Brand penalty applies |
| XCOPRI ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 4 | PA | galantamine hydrobromide er oral capsule extended release 24 hour 16 mg, 24 mg, 8 mg | 2 | |
| XCOPRI ORAL TABLET THERAPY PACK 100 & 150 MG, 14 X 12.5 MG & 14 X 25 MG, 14 X 150 MG & 14 X200 MG, 14 X 50 MG & 14 X100 MG, 150 & 200 MG, 50 & 200 MG | 4 | PA | galantamine hydrobromide oral solution 4 mg/ml | 2 | |
| ZARONTIN ORAL CAPSULE 250 MG | 4 | | galantamine hydrobromide oral tablet 12 mg, 4 mg, 8 mg | 2 | |
| ZARONTIN ORAL SOLUTION 250 MG/5ML | 4 | | memantine hcl er oral capsule extended release 24 hour 14 mg, 21 mg, 28 mg, 7 mg | 2 | |
| ZONEGRAN ORAL CAPSULE 100 MG, 25 MG | 4 | | memantine hcl oral solution 10 mg/5ml, 2 mg/ml | 2 | |
| ZONISADE ORAL SUSPENSION 100 MG/5ML | 2 | | memantine hcl oral tablet 10 mg, 28 x 5 mg & 21 x 10 mg, 5 mg | 2 | |
| zonisamide oral capsule 100 mg, 25 mg, 50 mg | 2 | | NAMENDA ORAL TABLET 10 MG, 5 MG | 4 | Brand penalty applies |
| ZTALMY ORAL SUSPENSION 50 MG/ML | 6 | PA | NAMENDA TITRATION PAK ORAL TABLET 28 X 5 MG & 21 X 10 MG | 4 | Brand penalty applies |
| Antidementia Agents - Drugs for Alzheimer's Disease and Dementia | | | NAMENDA XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 14 MG, 21 MG, 28 MG, 7 MG | 4 | Brand penalty applies |
| ADLARITY TRANSDERMAL PATCH WEEKLY 10 MG/DAY, 5 MG/DAY | 4 | | NAMENDA XR TITRATION PACK ORAL CAPSULE EXTENDED RELEASE 24 HOUR 7 & 14 & 21 | 4 | |
| ARICEPT ORAL TABLET 10 MG, 23 MG, 5 MG | 4 | Brand penalty applies | | | |
| donepezil hcl oral tablet 10 mg, 23 mg, 5 mg | 2 | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------------------------------|-----------|----------------------------|
| NAMZARIC ORAL CAPSULE ER 24 HOUR THERAPY PACK 7 & 14 & 21 & 28 -10 MG | 4 | |
| NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG | 4 | |
| RAZADYNE ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 16 MG, 24 MG, 8 MG | 4 | Brand penalty applies |
| rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg | 2 | |
| rivastigmine transdermal patch 24 hour 13.3 mg/24hr, 4.6 mg/24hr, 9.5 mg/24hr | 2 | |
| Antidepressants | | |
| amitriptyline hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg | 2 | |
| amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg | 2 | |
| ANAFRANIL ORAL CAPSULE 25 MG, 50 MG, 75 MG | 4 | Brand penalty applies |
| APLENZIN ORAL TABLET EXTENDED RELEASE 24 HOUR 174 MG, 348 MG, 522 MG | 4 | ST; QL (30 EA per 30 days) |
| bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg, 150 mg, 200 mg | 2 | |
| bupropion hcl er (xl) oral tablet extended release 24 hour 150 mg, 300 mg | 2 | |

| Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------------------------|-----------|-----------------------|
| bupropion hcl oral tablet 100 mg, 75 mg | 2 | |
| CELEXA ORAL TABLET 10 MG, 20 MG, 40 MG | 4 | Brand penalty applies |
| chlordiazepoxide-amitriptyline oral tablet 10-25 mg, 5-12.5 mg | 2 | |
| CITALOPRAM HYDROBROMIDE ORAL CAPSULE 30 MG | 3 | |
| citalopram hydrobromide oral solution 10 mg/5ml | 2 | |
| citalopram hydrobromide oral tablet 10 mg, 20 mg, 40 mg | 1 | |
| clomipramine hcl oral capsule 25 mg, 50 mg, 75 mg | 2 | |
| CYMBALTA ORAL CAPSULE DELAYED RELEASE PARTICLES 20 MG, 30 MG, 60 MG | 4 | Brand penalty applies |
| desipramine hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg | 2 | |
| DESVENLAFAXINE ER ORAL TABLET EXTENDED RELEASE 24 HOUR 100 MG, 50 MG | 4 | PA |
| desvenlafaxine succinate er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg | 2 | PA |
| doxepin hcl oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg | 2 | |
| doxepin hcl oral concentrate 10 mg/ml | 2 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------|-----------|-----------------------|--------------------------------------------------------------------------------------|-----------|-----------------------|
| duloxetine hcl oral capsule delayed release particles 20 mg, 30 mg, 60 mg | 2 | | imipramine hcl oral tablet 10 mg, 25 mg, 50 mg | 2 | |
| EFFEXOR XR ORAL CAPSULE EXTENDED RELEASE 24 HOUR 150 MG, 37.5 MG, 75 MG | 4 | Brand penalty applies | imipramine pamoate oral capsule 100 mg, 125 mg, 150 mg, 75 mg | 2 | |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24HR, 6 MG/24HR, 9 MG/24HR | 3 | | LEXAPRO ORAL TABLET 10 MG, 20 MG, 5 MG | 4 | Brand penalty applies |
| escitalopram oxalate oral solution 5 mg/5ml | 2 | | LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG | 4 | PA |
| escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg | 2 | | maprotiline hcl oral tablet 25 mg, 50 mg, 75 mg | 2 | |
| FETZIMA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 20 MG, 40 MG, 80 MG | 4 | PA | MARPLAN ORAL TABLET 10 MG | 4 | |
| FETZIMA TITRATION ORAL CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG | 4 | PA | mirtazapine oral tablet 15 mg, 30 mg, 45 mg, 7.5 mg | 2 | |
| fluoxetine hcl oral capsule 10 mg, 20 mg, 40 mg | 1 | | mirtazapine oral tablet dispersible 15 mg, 30 mg, 45 mg | 2 | |
| fluoxetine hcl oral capsule delayed release 90 mg | 2 | | NARDIL ORAL TABLET 15 MG | 4 | Brand penalty applies |
| fluoxetine hcl oral solution 20 mg/5ml | 2 | | nefazodone hcl oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg | 2 | |
| fluoxetine hcl oral tablet 10 mg, 20 mg | 2 | | NORPRAMIN ORAL TABLET 10 MG, 25 MG | 4 | Brand penalty applies |
| fluvoxamine maleate er oral capsule extended release 24 hour 100 mg, 150 mg | 2 | | nortriptyline hcl oral capsule 10 mg, 25 mg, 50 mg, 75 mg | 2 | |
| fluvoxamine maleate oral tablet 100 mg, 25 mg, 50 mg | 2 | | nortriptyline hcl oral solution 10 mg/5ml | 2 | |
| | | | olanzapine-fluoxetine hcl oral capsule 12-25 mg, 12-50 mg, 3-25 mg, 6-25 mg, 6-50 mg | 2 | ST |
| | | | PAMELOR ORAL CAPSULE 10 MG, 25 MG, 50 MG, 75 MG | 4 | Brand penalty applies |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------------------------|-----------|---------------------------|---------------------------------------------------------------------------------|-----------|---------------------------|
| PARNATE ORAL TABLET 10 MG | 4 | Brand penalty applies | REMERON SOLTAB ORAL TABLET DISPERSIBLE 15 MG, 30 MG, 45 MG | 4 | Brand penalty applies |
| paroxetine hcl er oral tablet extended release 24 hour 12.5 mg, 25 mg, 37.5 mg | 2 | | SERTRALINE HCL ORAL CAPSULE 150 MG, 200 MG | 4 | |
| paroxetine hcl oral suspension 10 mg/5ml | 2 | | sertraline hcl oral concentrate 20 mg/ml | 2 | |
| paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg, 40 mg | 2 | | sertraline hcl oral tablet 100 mg, 25 mg, 50 mg | 1 | |
| PAXIL CR ORAL TABLET EXTENDED RELEASE 24 HOUR 12.5 MG, 25 MG, 37.5 MG | 4 | Brand penalty applies | SPRAVATO (56 MG DOSE) NASAL SOLUTION THERAPY PACK 28 MG/DEVICE | 6 | PA; Specialty Medical |
| PAXIL ORAL SUSPENSION 10 MG/5ML | 3 | Brand penalty applies | SPRAVATO (84 MG DOSE) NASAL SOLUTION THERAPY PACK 28 MG/DEVICE | 6 | PA; Specialty Medical |
| PAXIL ORAL TABLET 10 MG, 20 MG, 30 MG, 40 MG | 4 | Brand penalty applies | SYMBYAX ORAL CAPSULE 12-50 MG, 3-25 MG, 6-25 MG, 6-50 MG | 4 | ST; Brand penalty applies |
| perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg | 2 | | tranylcypromine sulfate oral tablet 10 mg | 2 | |
| phenelzine sulfate oral tablet 15 mg | 2 | | trazodone hcl oral tablet 100 mg, 150 mg, 300 mg, 50 mg | 2 | |
| PRISTIQ ORAL TABLET EXTENDED RELEASE 24 HOUR 100 MG, 25 MG, 50 MG | 4 | PA; Brand penalty applies | trimipramine maleate oral capsule 100 mg, 25 mg, 50 mg | 2 | |
| protriptyline hcl oral tablet 10 mg, 5 mg | 2 | | TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 4 | PA |
| PROZAC ORAL CAPSULE 10 MG, 20 MG, 40 MG | 4 | Brand penalty applies | VENLAFAXINE BESYLATE ER ORAL TABLET EXTENDED RELEASE 24 HOUR 112.5 MG | 4 | |
| REMERON ORAL TABLET 15 MG, 30 MG | 4 | Brand penalty applies | venlafaxine hcl er oral capsule extended release 24 hour 150 mg, 37.5 mg, 75 mg | 2 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------------|-----------|---------------------------|---------------------------------------------------------------|-----------|----------------------------------------------|
| venlafaxine hcl oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg | 2 | | ANTIVERT ORAL TABLET CHEWABLE 25 MG | 4 | Brand penalty applies |
| VIIBRYD ORAL TABLET 10 MG, 20 MG, 40 MG | 4 | PA; Brand penalty applies | ANZEMET ORAL TABLET 100 MG, 50 MG | 3 | |
| VIIBRYD STARTER PACK ORAL KIT 10 & 20 MG | 4 | PA | aprepitant oral 80 & 125 mg | 2 | QL (6 EA per 30 days) |
| vilazodone hcl oral tablet 10 mg, 20 mg, 40 mg | 2 | PA | aprepitant oral capsule 125 mg, 40 mg, 80 & 125 mg, 80 mg | 2 | QL (6 EA per 30 days) |
| WELLBUTRIN SR ORAL TABLET EXTENDED RELEASE 12 HOUR 100 MG, 150 MG, 200 MG | 4 | Brand penalty applies | BARHEMSYS INTRAVENOUS SOLUTION 10 MG/4ML, 5 MG/2ML | GM | |
| WELLBUTRIN XL ORAL TABLET EXTENDED RELEASE 24 HOUR 150 MG, 300 MG | 4 | Brand penalty applies | CINVANTI INTRAVENOUS EMULSION 130 MG/18ML | GM | QL (6 ML per 30 days) |
| ZOLOFT ORAL CONCENTRATE 20 MG/ML | 4 | Brand penalty applies | compro rectal suppository 25 mg | 2 | |
| ZOLOFT ORAL TABLET 100 MG, 25 MG, 50 MG | 4 | Brand penalty applies | dimenhydrinate injection solution 50 mg/ml | GM | |
| Antiemetics - Drugs for Nausea and Vomiting | | | dronabinol oral capsule 10 mg, 2.5 mg, 5 mg | 2 | |
| AKYNZEO INTRAVENOUS SOLUTION 235-0.25 MG/20ML | GM | | droperidol injection solution 2.5 mg/ml | GM | |
| AKYNZEO INTRAVENOUS SOLUTION RECONSTITUTED 235-0.25 MG | GM | | DROPERIDOL INTRAVENOUS SOLUTION PREFILLED SYRINGE 0.625 MG/ML | GM | |
| AKYNZEO ORAL CAPSULE 300-0.5 MG | 4 | QL (3 EA per 21 days) | EMEND INTRAVENOUS SOLUTION RECONSTITUTED 150 MG | GM | PA |
| ANTIVERT ORAL TABLET 50 MG | 4 | | EMEND ORAL CAPSULE 80 MG | 4 | Brand penalty applies; QL (6 EA per 30 days) |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------------|-----------|----------------------------|----------------------------------------------------------------------|-----------|--------------------------|
| TRANSDERM SCOP (1.5 MG) TRANSDERMAL PATCH 72 HOUR 1 MG/3DAYS | 4 | Brand penalty applies | CANCIDAS INTRAVENOUS SOLUTION RECONSTITUTED 50 MG, 70 MG | GM | |
| TRANSDERM-SCOP TRANSDERMAL PATCH 72 HOUR 1 MG/3DAYS | 4 | Brand penalty applies | casposfungin acetate intravenous solution reconstituted 50 mg, 70 mg | GM | |
| trimethobenzamide hcl oral capsule 300 mg | 2 | | ciclopirox external solution 8 % | 2 | QL (13.2 ML per 30 days) |
| VARUBI (180 MG DOSE) ORAL TABLET THERAPY PACK 2 X 90 MG | 4 | QL (4 EA per 30 days) | ciclopirox external gel 0.77 % | 2 | |
| ZOFRAN ORAL TABLET 4 MG | 4 | Brand penalty applies | ciclopirox external shampoo 1 % | 2 | |
| ZUPLENZ ORAL FILM 4 MG, 8 MG | 4 | | ciclopirox external solution 8 % | 2 | QL (13.2 ML per 30 days) |
| Antifungals | | | ciclopirox olamine external cream 0.77 % | 2 | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | GM | | ciclopirox olamine external suspension 0.77 % | 2 | |
| ALA-QUIN EXTERNAL CREAM 3-0.5 % | 4 | | clotrimazole external cream 1 % | 2 | |
| ALCORTIN A EXTERNAL GEL 1-2-1 % | 4 | | clotrimazole external solution 1 % | 2 | |
| AMBISOME INTRAVENOUS SUSPENSION RECONSTITUTED 50 MG | GM | | clotrimazole mouth/throat troche 10 mg | 2 | |
| amphotericin b intravenous solution reconstituted 50 mg | GM | | clotrimazole-betamethasone external cream 1-0.05 % | 2 | |
| amphotericin b liposome intravenous suspension reconstituted 50 mg | GM | | clotrimazole-betamethasone external lotion 1-0.05 % | 2 | |
| ANCOBON ORAL CAPSULE 250 MG, 500 MG | 4 | Brand penalty applies | CORTI-SAV EXTERNAL CREAM 1-1 % | 4 | |
| BREXAFEMME ORAL TABLET 150 MG | 4 | PA; QL (4 EA per 30 fills) | CRESEMBA INTRAVENOUS SOLUTION RECONSTITUTED 372 MG | 6 | PA; Specialty Medical |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|------------------------------------------------------|-----------|----------------------------------------------|------------------------------------------------------------------------------------|-----------|-----------------------|
| VYEPTI INTRAVENOUS SOLUTION 100 MG/ML | 5 | PA; Specialty Medical | MESTINON ORAL TABLET 60 MG | 4 | Brand penalty applies |
| ZOLMITRIPTAN NASAL SOLUTION 2.5 MG | 4 | QL (6 EA per 30 days) | MESTINON ORAL TABLET EXTENDED RELEASE 180 MG | 4 | Brand penalty applies |
| zolmitriptan nasal solution 5 mg | 2 | QL (6 EA per 30 days) | neostigmine methylsulfate intravenous solution 10 mg/10ml, 5 mg/10ml | GM | |
| zolmitriptan oral tablet 2.5 mg, 5 mg | 2 | QL (9 EA per 30 days) | NEOSTIGMINE METHYLSULFATE INTRAVENOUS SOLUTION 3 MG/3ML, 5 MG/5ML | GM | |
| zolmitriptan oral tablet dispersible 2.5 mg, 5 mg | 2 | QL (9 EA per 30 days) | NEOSTIGMINE METHYLSULFATE INTRAVENOUS SOLUTION PREFILLED SYRINGE 4 MG/4ML | GM | |
| ZOMIG NASAL SOLUTION 2.5 MG | 4 | QL (6 EA per 30 days) | neostigmine methylsulfate solution prefilled syringe 3 mg/3ml intravenous 3 mg/3ml | GM | |
| ZOMIG NASAL SOLUTION 5 MG | 4 | Brand penalty applies; QL (6 EA per 30 days) | NEOSTIGMINE METHYLSULFATE SOLUTION PREFILLED SYRINGE 3 MG/3ML INTRAVENOUS 3 MG/3ML | GM | |
| ZOMIG ORAL TABLET 2.5 MG, 5 MG | 4 | Brand penalty applies; QL (9 EA per 30 days) | pyridostigmine bromide er oral tablet extended release 180 mg | 2 | |
| ZOMIG ZMT ORAL TABLET DISPERSIBLE 2.5 MG, 5 MG | 4 | Brand penalty applies; QL (9 EA per 30 days) | pyridostigmine bromide oral solution 60 mg/5ml | 2 | |
| Antimyasthenic Agents | | | pyridostigmine bromide oral tablet 30 mg, 60 mg | 2 | |
| BLOXIVERZ INTRAVENOUS SOLUTION 10 MG/10ML, 5 MG/10ML | GM | | REGONOL INTRAVENOUS SOLUTION 10 MG/2ML | GM | |
| GUANIDINE HCL ORAL TABLET 125 MG | 4 | | | | |
| MESTINON ORAL SOLUTION 60 MG/5ML | 4 | Brand penalty applies | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|----------------------------------------------------------|-----------|---------------------------|----------------------------------------------------------|-----------|-----------------------|
| ALIMTA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 500 MG | 6 | PA; Specialty Medical | ASPARLAS INTRAVENOUS SOLUTION 3750 UNIT/5ML | 6 | PA; Specialty Medical |
| ALIQOPA INTRAVENOUS SOLUTION RECONSTITUTED 60 MG | 6 | PA; Specialty Medical | AVASTIN INTRAVENOUS SOLUTION 100 MG/4ML, 400 MG/16ML | 6 | PA; Specialty Medical |
| ALKERAN INTRAVENOUS SOLUTION RECONSTITUTED 50 MG | 6 | PA; Specialty Medical | AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG | 6 | PA |
| ALKERAN ORAL TABLET 2 MG | 4 | PA; Brand penalty applies | azacitidine injection suspension reconstituted 100 mg | 6 | PA; Specialty Medical |
| ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG | 6 | PA | AZEDRA DOSIMETRIC INTRAVENOUS SOLUTION 15 MCI/ML | GM | |
| ALUNBRIG ORAL TABLET THERAPY PACK 90 & 180 MG | 6 | PA | AZEDRA THERAPEUTIC INTRAVENOUS SOLUTION 15 MCI/ML | GM | |
| anastrozole oral tablet 1 mg | 2 | | BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG | 6 | PA |
| ARIMIDEX ORAL TABLET 1 MG | 4 | Brand penalty applies | BAVENCIO INTRAVENOUS SOLUTION 200 MG/10ML | 6 | PA; Specialty Medical |
| AROMASIN ORAL TABLET 25 MG | 4 | Brand penalty applies | BELEODAQ INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | 6 | PA; Specialty Medical |
| ARRANON INTRAVENOUS SOLUTION 5 MG/ML | 6 | PA; Specialty Medical | BELRAPZO INTRAVENOUS SOLUTION 100 MG/4ML | 6 | PA; Specialty Medical |
| arsenic trioxide intravenous solution 10 mg/10ml | 6 | PA; Specialty Medical | BENDEKA INTRAVENOUS SOLUTION 100 MG/4ML | 6 | PA; Specialty Medical |
| ARZERRA INTRAVENOUS CONCENTRATE 100 MG/5ML, 1000 MG/50ML | 6 | PA; Specialty Medical | BESPONSA INTRAVENOUS SOLUTION RECONSTITUTED 0.9 MG | 6 | PA; Specialty Medical |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------|-----------|-----------------------|-------------------------------------------------------------------------|-----------|-----------------------|
| CARVYKTI INTRAVENOUS SUSPENSION 100000000 CELLS | 6 | PA; Specialty Medical | CYCLOPHOSPHAMIDE INTRAVENOUS SOLUTION 1 GM/5ML, 2 GM/10ML, 500 MG/2.5ML | 6 | PA; Specialty Medical |
| CASODEX ORAL TABLET 50 MG | 4 | Brand penalty applies | cyclophosphamide oral capsule 25 mg, 50 mg | 2 | PA |
| cisplatin intravenous solution 100 mg/100ml, 200 mg/200ml, 50 mg/50ml | GM | PA | CYCLOPHOSPHAMIDE ORAL TABLET 25 MG, 50 MG | 4 | |
| cladribine intravenous solution 10 mg/10ml | 6 | PA; Specialty Medical | CYRAMZA INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML | 6 | PA; Specialty Medical |
| clofarabine intravenous solution 1 mg/ml | 6 | PA; Specialty Medical | cytarabine (pf) injection solution 100 mg/ml, 20 mg/ml | 6 | PA; Specialty Medical |
| CLOLAR INTRAVENOUS SOLUTION 1 MG/ML | 6 | PA; Specialty Medical | cytarabine injection solution 20 mg/ml | 6 | PA; Specialty Medical |
| COMETRIQ ORAL KIT 20 MG, 3 X 20 MG & 80 MG, 80 & 20 MG | 6 | PA | dacarbazine intravenous solution reconstituted 100 mg, 200 mg | 6 | PA; Specialty Medical |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 6 | PA | DACOGEN INTRAVENOUS SOLUTION RECONSTITUTED 50 MG | 6 | PA; Specialty Medical |
| COSELA INTRAVENOUS SOLUTION RECONSTITUTED 300 MG | 6 | PA; Specialty Medical | dactinomycin intravenous solution reconstituted 0.5 mg | 6 | PA; Specialty Medical |
| COSMEGEN INTRAVENOUS SOLUTION RECONSTITUTED 0.5 MG | 6 | PA; Specialty Medical | DANYELZA INTRAVENOUS SOLUTION 40 MG/10ML | 6 | PA; Specialty Medical |
| COTELLIC ORAL TABLET 20 MG | 6 | PA | DARZALEX FASPRO SUBCUTANEOUS SOLUTION 1800-30000 MG-UT/15ML | 6 | PA; Specialty Medical |
| cyclophosphamide injection solution reconstituted 1 gm, 2 gm, 500 mg | 6 | PA; Specialty Medical | DARZALEX INTRAVENOUS SOLUTION 100 MG/5ML, 400 MG/20ML | 6 | PA; Specialty Medical |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------|-----------|-----------------------|--------------------------------------------------------------|-----------|-----------------------|
| daunorubicin hcl intravenous solution 20 mg/4ml, 50 mg/10ml | GM | PA | ELZONRIS INTRAVENOUS SOLUTION 1000 MCG/ML | 6 | PA; Specialty Medical |
| DAURISMO ORAL TABLET 100 MG, 25 MG | 6 | PA | EMCYT ORAL CAPSULE 140 MG | 3 | PA |
| decitabine intravenous solution reconstituted 50 mg | 6 | PA; Specialty Medical | EMPLICITI INTRAVENOUS SOLUTION RECONSTITUTED 300 MG, 400 MG | 6 | PA; Specialty Medical |
| dexrazoxane hcl intravenous solution reconstituted 250 mg, 500 mg | GM | | ENHERTU INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 6 | PA; Specialty Medical |
| docetaxel intravenous concentrate 160 mg/8ml, 20 mg/ml, 80 mg/4ml | 6 | PA; Specialty Medical | epirubicin hcl intravenous solution 200 mg/100ml, 50 mg/25ml | 6 | PA; Specialty Medical |
| docetaxel intravenous solution 160 mg/16ml, 20 mg/2ml, 80 mg/8ml | 6 | PA; Specialty Medical | ERBITUX INTRAVENOUS SOLUTION 100 MG/50ML, 200 MG/100ML | 6 | PA; Specialty Medical |
| DOXIL INTRAVENOUS INJECTABLE 2 MG/ML | 6 | PA; Specialty Medical | ERIVEDGE ORAL CAPSULE 150 MG | 6 | PA |
| doxorubicin hcl intravenous solution 2 mg/ml | GM | PA | ERLEADA ORAL TABLET 60 MG | 6 | PA |
| doxorubicin hcl intravenous solution reconstituted 10 mg, 50 mg | GM | PA | erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg | 5 | PA |
| doxorubicin hcl liposomal intravenous injectable 2 mg/ml | 6 | PA; Specialty Medical | ERWINASE INJECTION SOLUTION RECONSTITUTED 10000 UNIT | 6 | PA; Specialty Medical |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG | 4 | | ERWINAZE INJECTION SOLUTION RECONSTITUTED 10000 UNIT | 6 | PA; Specialty Medical |
| ELITEK INTRAVENOUS SOLUTION RECONSTITUTED 1.5 MG, 7.5 MG | 6 | Specialty Medical | ETOPOPHOS INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 6 | PA; Specialty Medical |
| ELLECE INTRAVENOUS SOLUTION 200 MG/100ML, 50 MG/25ML | 6 | PA; Specialty Medical | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------------------------|-----------|-----------------------|-------------------------------------------------------------------------------------------------|-----------|-----------------------|
| ONTRUZANT INTRAVENOUS SOLUTION RECONSTITUTED 150 MG, 420 MG | 5 | PA; Specialty Medical | paraplatin intravenous solution 1000 mg/100ml, 150 mg/15ml, 450 mg/45ml, 50 mg/5ml, 600 mg/60ml | GM | PA |
| ONUREG ORAL TABLET 200 MG, 300 MG | 6 | PA | PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 6 | PA |
| OPDIVO INTRAVENOUS SOLUTION 100 MG/10ML, 120 MG/12ML, 240 MG/24ML, 40 MG/4ML | 6 | PA; Specialty Medical | PEMETREXED DISODIUM INTRAVENOUS SOLUTION 1 GM/40ML, 100 MG/4ML, 500 MG/20ML, 850 MG/34ML | 6 | PA; Specialty Medical |
| OPDUALAG INTRAVENOUS SOLUTION 240-80 MG/20ML | 6 | PA; Specialty Medical | pemetrexed disodium intravenous solution reconstituted 100 mg, 1000 mg, 500 mg, 750 mg | 6 | PA; Specialty Medical |
| ORGOVYX ORAL TABLET 120 MG | 6 | PA | PEMETREXED DITROMETHAMINE INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 500 MG | 6 | PA; Specialty Medical |
| oxaliplatin intravenous solution 100 mg/20ml, 50 mg/10ml | GM | PA | PEMETREXED INTRAVENOUS SOLUTION 1 GM/40ML, 100 MG/4ML, 500 MG/20ML | 6 | PA; Specialty Medical |
| oxaliplatin intravenous solution reconstituted 100 mg, 50 mg | GM | PA | PEMFEXY INTRAVENOUS SOLUTION 500 MG/20ML | 6 | PA; Specialty Medical |
| paclitaxel intravenous concentrate 100 mg/16.7ml, 150 mg/25ml, 30 mg/5ml, 300 mg/50ml | 6 | PA; Specialty Medical | PEPAXTO INTRAVENOUS SOLUTION RECONSTITUTED 20 MG | 6 | PA; Specialty Medical |
| PACLITAXEL PROTEIN-BOUND PART INTRAVENOUS SUSPENSION RECONSTITUTED 100 MG | 6 | PA; Specialty Medical | PERJETA INTRAVENOUS SOLUTION 420 MG/14ML | 6 | PA; Specialty Medical |
| PADCEV INTRAVENOUS SOLUTION RECONSTITUTED 20 MG, 30 MG | 6 | PA; Specialty Medical | | | |
| PANRETIN EXTERNAL GEL 0.1 % | 4 | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|----------------------------------------------------------------------------------------|-----------|-----------------------------|------------------------------------------------------------------------------------------------------|-----------|-----------------------------|
| PHESGO SUBCUTANEOUS SOLUTION 60-60-2000 MG-MG-U/ML, 80-40- 2000 MG-MG-U/ML | 6 | PA; Specialty Medical | QUADRAMET INTRAVENOUS SOLUTION 1850 MBQ/ML | 6 | Specialty Medical |
| PHOTOFRIN INTRAVENOUS SOLUTION RECONSTITUTED 75 MG | 6 | PA; Specialty Medical | RETEVMO ORAL CAPSULE 40 MG, 80 MG | 6 | PA |
| PIQRAY ORAL TABLET THERAPY PACK 2 X 150 MG, 200 & 50 MG, 200 MG | 6 | PA | REVLIMID ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG | 6 | PA |
| PLUVICTO INTRAVENOUS SOLUTION 1000 MBQ/ML | 6 | PA; Specialty Medical | RIABNI INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML | 5 | PA; Specialty Medical |
| POLIVY INTRAVENOUS SOLUTION RECONSTITUTED 140 MG, 30 MG | 6 | PA; Specialty Medical | RITUXAN HYCELA SUBCUTANEOUS SOLUTION 1400-23400 MG -UT/11.7ML, 1600- 26800 MG -UT/13.4ML | 6 | PA; Specialty Medical |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 6 | PA | RITUXAN INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML | 6 | PA; Specialty Medical |
| PORTRAZZA INTRAVENOUS SOLUTION 800 MG/50ML | 6 | PA; Specialty Medical | ROMIDEPSIN INTRAVENOUS SOLUTION 27.5 MG/5.5ML | 6 | PA; Specialty Medical |
| POTELIGEO INTRAVENOUS SOLUTION 20 MG/5ML | 6 | PA; Specialty Medical | romidepsin intravenous solution reconstituted 10 mg | 6 | PA; Specialty Medical |
| PROLEUKIN INTRAVENOUS SOLUTION RECONSTITUTED 22000000 UNIT | 6 | PA; Specialty Medical | ROZLYTREK ORAL CAPSULE 100 MG, 200 MG | 6 | PA |
| PURIXAN ORAL SUSPENSION 2000 MG/100ML | 4 | | RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 6 | PA |
| QINLOCK ORAL TABLET 50 MG | 6 | PA | RUXIENCE INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML | 5 | PA; Specialty Medical |
| | | | RYBREVANT INTRAVENOUS SOLUTION 350 MG/7ML | 6 | PA; Specialty Medical |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|----------------------------------------------------------------|-----------|-----------------------|------------------------------------------------------------------|-----------|-----------------------------|
| RYDAPT ORAL CAPSULE 25 MG | 6 | PA | TABRECTA ORAL TABLET 150 MG, 200 MG | 6 | PA |
| RYLAZE INTRAMUSCULAR SOLUTION 10 MG/0.5ML | 6 | PA; Specialty Medical | TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 6 | PA |
| SARCLISA INTRAVENOUS SOLUTION 100 MG/5ML, 500 MG/25ML | 6 | PA; Specialty Medical | TAGRISSO ORAL TABLET 40 MG, 80 MG | 6 | PA |
| SCEMBLIX ORAL TABLET 20 MG, 40 MG | 6 | PA | TALZENNA ORAL CAPSULE 0.25 MG, 0.5 MG, 0.75 MG, 1 MG | 6 | PA |
| sorafenib tosylate oral tablet 200 mg | 6 | PA | tamoxifen citrate oral tablet 10 mg, 20 mg | PV | |
| SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG | 6 | PA | TARCEVA ORAL TABLET 100 MG, 150 MG, 25 MG | 6 | PA |
| STIVARGA ORAL TABLET 40 MG | 6 | PA | TARGRETIN EXTERNAL GEL 1 % | 6 | PA |
| STRONTIUM CHLORIDE SR-89 INTRAVENOUS SOLUTION 1 MCI/ML | GM | | TARGRETIN ORAL CAPSULE 75 MG | 6 | PA |
| sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg | 5 | PA | TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG | 6 | PA; QL (120 EA per 30 days) |
| SUTENT ORAL CAPSULE 12.5 MG, 25 MG, 37.5 MG, 50 MG | 6 | PA | TAZVERIK ORAL TABLET 200 MG | 6 | PA |
| SYLVANT INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 400 MG | 6 | PA; Specialty Medical | TECARTUS INTRAVENOUS SUSPENSION 100000000 CELLS, 200000000 CELLS | 6 | PA; Specialty Medical |
| SYNRIBO SUBCUTANEOUS SOLUTION RECONSTITUTED 3.5 MG | 6 | PA | TECENTRIQ INTRAVENOUS SOLUTION 1200 MG/20ML, 840 MG/14ML | 6 | PA; Specialty Medical |
| TABLOID ORAL TABLET 40 MG | 3 | | TEMODAR INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 6 | PA; Specialty Medical |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------|-----------|-----------------------|--------------------------------------------------------------------|-----------|-----------------------|
| TEMODAR ORAL CAPSULE 100 MG, 140 MG, 180 MG, 20 MG, 250 MG | 6 | PA | toremifene citrate oral tablet 60 mg | 2 | PA |
| temozolomide oral capsule 100 mg, 140 mg, 180 mg, 20 mg, 250 mg, 5 mg | 5 | PA | TOTECT INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | GM | |
| teniposide intravenous solution 10 mg/ml | 6 | PA; Specialty Medical | TRAZIMERA INTRAVENOUS SOLUTION RECONSTITUTED 150 MG, 420 MG | 5 | PA; Specialty Medical |
| TEPADINA INJECTION SOLUTION RECONSTITUTED 100 MG, 15 MG | 6 | PA; Specialty Medical | TREANDA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 25 MG | 6 | PA; Specialty Medical |
| TEPMETKO ORAL TABLET 225 MG | 6 | PA | tretinoin oral capsule 10 mg | 2 | PA |
| THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG | 6 | PA | TRODELVY INTRAVENOUS SOLUTION RECONSTITUTED 180 MG | 6 | PA; Specialty Medical |
| thiotepa injection solution reconstituted 100 mg, 15 mg | 6 | PA; Specialty Medical | TRUSELTIQ (100MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 100 MG | 6 | PA |
| TIBSOVO ORAL TABLET 250 MG | 6 | PA | TRUSELTIQ (125MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 100 & 25 MG | 6 | PA |
| TICE BCG INTRAVESICAL SUSPENSION RECONSTITUTED 50 MG | GM | PA | TRUSELTIQ (50MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 25 MG | 6 | PA |
| TIVDAK INTRAVENOUS SOLUTION RECONSTITUTED 40 MG | GM | | TRUSELTIQ (75MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 25 MG | 6 | PA |
| toposar intravenous solution 1 gm/50ml, 100 mg/5ml, 500 mg/25ml | GM | PA | TRUXIMA INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML | 5 | PA; Specialty Medical |
| topotecan hcl intravenous solution 4 mg/4ml | GM | PA | | | |
| topotecan hcl intravenous solution reconstituted 4 mg | GM | PA | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------|-----------|-----------------------|---------------------------------------------------------------|-----------|-----------------------|
| TUKYSA ORAL TABLET 150 MG, 50 MG | 6 | PA | VIJOICE ORAL TABLET THERAPY PACK 125 MG, 200 & 50 MG, 50 MG | 6 | PA |
| TURALIO ORAL CAPSULE 200 MG | 6 | PA | vinblastine sulfate intravenous solution 1 mg/ml | 6 | PA; Specialty Medical |
| TYKERB ORAL TABLET 250 MG | 6 | PA | vincasar pfs intravenous solution 1 mg/ml | GM | PA |
| UNITUXIN INTRAVENOUS SOLUTION 17.5 MG/5ML | 6 | PA; Specialty Medical | vincristine sulfate intravenous solution 1 mg/ml | GM | PA |
| UVADEX EXTRACORPOREAL SOLUTION 20 MCG/ML | GM | | vinorelbine tartrate intravenous solution 10 mg/ml, 50 mg/5ml | 6 | PA; Specialty Medical |
| VALCHLOR EXTERNAL GEL 0.016 % | 6 | PA | VITRAKVI ORAL CAPSULE 100 MG, 25 MG | 6 | PA |
| valrubicin intravesical solution 40 mg/ml | 6 | PA; Specialty Medical | VITRAKVI ORAL SOLUTION 20 MG/ML | 6 | PA |
| VALSTAR INTRAVESICAL SOLUTION 40 MG/ML | 6 | PA; Specialty Medical | VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 6 | PA |
| VECTIBIX INTRAVENOUS SOLUTION 100 MG/5ML, 400 MG/20ML | 6 | PA; Specialty Medical | VONJO ORAL CAPSULE 100 MG | 6 | PA |
| VELCADE INJECTION SOLUTION RECONSTITUTED 3.5 MG | 6 | PA; Specialty Medical | VORAXAZE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT | GM | |
| VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG | 6 | PA | VOTRIENT ORAL TABLET 200 MG | 6 | PA |
| VENCLEXTA STARTING PACK ORAL TABLET THERAPY PACK 10 & 50 & 100 MG | 6 | PA | VYXEOS INTRAVENOUS SUSPENSION RECONSTITUTED 44-100 MG | 6 | PA; Specialty Medical |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 6 | PA | WELIREG ORAL TABLET 40 MG | 6 | PA |
| VIDAZA INJECTION SUSPENSION RECONSTITUTED 100 MG | 6 | PA; Specialty Medical | XALKORI ORAL CAPSULE 200 MG, 250 MG | 6 | PA |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------|-----------|-----------------------|
| XELODA ORAL TABLET 150 MG, 500 MG | 6 | PA |
| XOFIGO INTRAVENOUS SOLUTION 30 MCCI/ML | 6 | PA; Specialty Medical |
| XOSPATA ORAL TABLET 40 MG | 6 | PA |
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG, 50 MG | 6 | PA |
| XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG, 40 MG | 6 | PA |
| XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG, 40 MG | 6 | PA |
| XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG, 60 MG | 6 | PA |
| XPOVIO (60 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 6 | PA |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG, 40 MG | 6 | PA |
| XPOVIO (80 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 6 | PA |
| XTANDI ORAL CAPSULE 40 MG | 6 | PA |
| XTANDI ORAL TABLET 40 MG, 80 MG | 6 | PA |
| YERVOY INTRAVENOUS SOLUTION 200 MG/40ML, 50 MG/10ML | 6 | PA; Specialty Medical |

| Drug Name | Drug Tier | Notes |
|------------------------------------------------------|-----------|-----------------------|
| YESCARTA INTRAVENOUS SUSPENSION 200000000 CELLS | 6 | PA; Specialty Medical |
| YONDELIS INTRAVENOUS SOLUTION RECONSTITUTED 1 MG | 6 | PA; Specialty Medical |
| YONSA ORAL TABLET 125 MG | 6 | PA |
| ZALTRAP INTRAVENOUS SOLUTION 100 MG/4ML, 200 MG/8ML | 6 | PA; Specialty Medical |
| ZANOSAR INTRAVENOUS SOLUTION RECONSTITUTED 1 GM | 6 | PA; Specialty Medical |
| ZEJULA ORAL CAPSULE 100 MG | 6 | PA |
| ZELBORAF ORAL TABLET 240 MG | 6 | PA |
| ZEPZELCA INTRAVENOUS SOLUTION RECONSTITUTED 4 MG | 6 | PA; Specialty Medical |
| ZEVALIN Y-90 INTRAVENOUS KIT 3.2 MG/2ML | 6 | Specialty Medical |
| ZIRABEV INTRAVENOUS SOLUTION 100 MG/4ML, 400 MG/16ML | 5 | PA; Specialty Medical |
| ZOLINZA ORAL CAPSULE 100 MG | 6 | PA |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 6 | PA |
| ZYKADIA ORAL TABLET 150 MG | 6 | PA |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------|-----------|-----------------------|
| ZYNLONTA INTRAVENOUS SOLUTION RECONSTITUTED 10 MG | 6 | PA; Specialty Medical |
| ZYTIGA ORAL TABLET 250 MG, 500 MG | 6 | PA |
| Antiparasitics | | |
| albendazole oral tablet 200 mg | 2 | |
| ALBENZA ORAL TABLET 200 MG | 4 | Brand penalty applies |
| ALINIA ORAL SUSPENSION RECONSTITUTED 100 MG/5ML | 4 | |
| ALINIA ORAL TABLET 500 MG | 4 | Brand penalty applies |
| ARAKODA ORAL TABLET 100 MG | 3 | |
| ARTESUNATE INTRAVENOUS SOLUTION RECONSTITUTED 110 MG | GM | |
| atovaquone oral suspension 750 mg/5ml | 2 | |
| atovaquone-proguanil hcl oral tablet 250-100 mg, 62.5-25 mg | 2 | |
| BENZNIDAZOLE ORAL TABLET 100 MG, 12.5 MG | 4 | |
| BILTRICIDE ORAL TABLET 600 MG | 4 | Brand penalty applies |
| chloroquine phosphate oral tablet 250 mg, 500 mg | 2 | |
| COARTEM ORAL TABLET 20-120 MG | 3 | |

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------|-----------|-----------------------|
| crotan external lotion 10 % | 2 | PA |
| DARAPRIM ORAL TABLET 25 MG | 6 | |
| ELIMITE EXTERNAL CREAM 5 % | 4 | Brand penalty applies |
| EMVERM ORAL TABLET CHEWABLE 100 MG | 4 | |
| hydroxychloroquine sulfate oral tablet 100 mg, 200 mg, 300 mg, 400 mg | 2 | |
| IMPAVIDO ORAL CAPSULE 50 MG | 6 | PA |
| ivermectin external lotion 0.5 % | 2 | |
| ivermectin oral tablet 3 mg | 2 | PA |
| KRINTAFEL ORAL TABLET 150 MG | 3 | QL (2 EA per 30 days) |
| LAMPIT ORAL TABLET 120 MG, 30 MG | 4 | |
| lindane external shampoo 1 % | 2 | |
| MALARONE ORAL TABLET 250-100 MG, 62.5-25 MG | 4 | Brand penalty applies |
| malathion external lotion 0.5 % | 2 | |
| mefloquine hcl oral tablet 250 mg | 2 | |
| MEPRON ORAL SUSPENSION 750 MG/5ML | 4 | Brand penalty applies |
| NATROBA EXTERNAL SUSPENSION 0.9 % | 4 | Brand penalty applies |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------------------------------------------------------|-----------|-----------------------|
| NEBUPENT INHALATION SOLUTION RECONSTITUTED 300 MG | 4 | Brand penalty applies |
| nitazoxanide oral tablet 500 mg | 2 | |
| OVIDE EXTERNAL LOTION 0.5 % | 4 | Brand penalty applies |
| PENTAM INJECTION SOLUTION RECONSTITUTED 300 MG | GM | |
| pentamidine isethionate inhalation solution reconstituted 300 mg | 2 | |
| pentamidine isethionate injection solution reconstituted 300 mg | GM | |
| permethrin external cream 5 % | 2 | |
| PLAQUENIL ORAL TABLET 200 MG | 4 | Brand penalty applies |
| praziquantel oral tablet 600 mg | 2 | |
| primaquine phosphate oral tablet 26.3 (15 base) mg | 2 | |
| pyrimethamine oral tablet 25 mg | 6 | |
| PYRIMETHAMINE-LEUCOVORIN ORAL CAPSULE 12.5-2.5 MG, 25-10 MG, 25-5 MG, 50-10 MG, 50-20 MG, 50-25 MG, 75-25 MG | 4 | |
| QUALAQUIN ORAL CAPSULE 324 MG | 4 | Brand penalty applies |
| quinine sulfate oral capsule 324 mg | 2 | |

| Drug Name | Drug Tier | Notes |
|-------------------------------------------------------------------------|-----------|---------------------------|
| SKLICE EXTERNAL LOTION 0.5 % | 4 | Brand penalty applies |
| spinosad external suspension 0.9 % | 2 | |
| STROMECTOL ORAL TABLET 3 MG | 4 | PA; Brand penalty applies |
| sulfurated lime external solution | 2 | |
| Antiparkinson Agents | | |
| amantadine hcl oral capsule 100 mg | 2 | |
| amantadine hcl oral solution 50 mg/5ml | 2 | |
| amantadine hcl oral tablet 100 mg | 2 | |
| APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE 30 MG/3ML | 6 | PA |
| apomorphine hcl subcutaneous solution cartridge 30 mg/3ml | 6 | PA |
| AZILECT ORAL TABLET 0.5 MG, 1 MG | 4 | Brand penalty applies |
| benztropine mesylate injection solution 1 mg/ml | GM | |
| benztropine mesylate oral tablet 0.5 mg, 1 mg, 2 mg | 1 | |
| bromocriptine mesylate oral capsule 5 mg | 2 | |
| bromocriptine mesylate oral tablet 2.5 mg | 2 | |
| carbidopa oral tablet 25 mg | 2 | |
| carbidopa-levodopa er oral tablet extended release 25-100 mg, 50-200 mg | 2 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------|
| carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg | 2 | | NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24HR, 2 MG/24HR, 3 MG/24HR, 4 MG/24HR, 6 MG/24HR, 8 MG/24HR | 4 | |
| carbidopa-levodopa oral tablet dispersible 10-100 mg, 25-100 mg, 25-250 mg | 2 | | NOURIANZ ORAL TABLET 20 MG, 40 MG | 6 | PA |
| carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg | 2 | | ONGENTYS ORAL CAPSULE 25 MG, 50 MG | 4 | PA |
| COGENTIN INJECTION SOLUTION 1 MG/ML | GM | | PARLODEL ORAL CAPSULE 5 MG | 4 | Brand penalty applies |
| COMTAN ORAL TABLET 200 MG | 4 | Brand penalty applies | PARLODEL ORAL TABLET 2.5 MG | 4 | Brand penalty applies |
| DHIVY ORAL TABLET 25-100 MG | 4 | | pramipexole dihydrochloride er oral tablet extended release 24 hour 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg | 2 | |
| entacapone oral tablet 200 mg | 2 | | pramipexole dihydrochloride oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg | 2 | |
| INBRIJA INHALATION CAPSULE 42 MG | 6 | PA | rasagiline mesylate oral tablet 0.5 mg, 1 mg | 2 | |
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 6 | PA | ropinirole hcl er oral tablet extended release 24 hour 12 mg, 2 mg, 4 mg, 6 mg, 8 mg | 2 | |
| KYNMOBI TITRATION KIT SUBLINGUAL KIT 10/15/20/25/30 MG | 6 | PA | ropinirole hcl oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg | 2 | |
| LODOSYN ORAL TABLET 25 MG | 4 | Brand penalty applies | RYTARY ORAL CAPSULE EXTENDED RELEASE 23.75-95 MG, 36.25-145 MG, 48.75-195 MG, 61.25-245 MG | 4 | |
| MIRAPEX ER ORAL TABLET EXTENDED RELEASE 24 HOUR 0.375 MG, 0.75 MG, 1.5 MG, 2.25 MG, 3 MG, 3.75 MG, 4.5 MG | 4 | Brand penalty applies | selegiline hcl oral capsule 5 mg | 2 | |
| MIRAPEX ORAL TABLET 0.125 MG, 0.5 MG, 0.75 MG, 1 MG | 4 | Brand penalty applies | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-----------------------------------------------------|-----------|-----------------------|-------------------------------------------------------------------------|-----------|-----------------------|
| selegiline hcl oral tablet 5 mg | 2 | | AGGRASTAT INTRAVENOUS SOLUTION 12.5-0.9 MG/250ML-%, 5-0.9 MG/100ML-% | GM | |
| SINEMET ORAL TABLET 10-100 MG, 25-100 MG, 25-250 MG | 4 | Brand penalty applies | aspirin-dipyridamole er oral capsule extended release 12 hour 25-200 mg | 2 | |
| STALEVO 100 ORAL TABLET 25-100-200 MG | 4 | Brand penalty applies | BRILINTA ORAL TABLET 60 MG, 90 MG | 3 | |
| STALEVO 125 ORAL TABLET 31.25-125-200 MG | 4 | Brand penalty applies | CABLIVI INJECTION KIT 11 MG | 6 | PA |
| STALEVO 150 ORAL TABLET 37.5-150-200 MG | 4 | Brand penalty applies | cilostazol oral tablet 100 mg, 50 mg | 2 | |
| STALEVO 200 ORAL TABLET 50-200-200 MG | 4 | Brand penalty applies | clopidogrel bisulfate oral tablet 300 mg | 2 | |
| STALEVO 50 ORAL TABLET 12.5-50-200 MG | 4 | Brand penalty applies | clopidogrel bisulfate oral tablet 75 mg | 1 | |
| STALEVO 75 ORAL TABLET 18.75-75-200 MG | 4 | Brand penalty applies | DEFITELIO INTRAVENOUS SOLUTION 200 MG/2.5ML | GM | |
| TASMAR ORAL TABLET 100 MG | 4 | Brand penalty applies | dipyridamole oral tablet 25 mg, 50 mg, 75 mg | 2 | |
| tolcapone oral tablet 100 mg | 2 | | EFFIENT ORAL TABLET 10 MG, 5 MG | 4 | Brand penalty applies |
| trihexyphenidyl hcl oral solution 0.4 mg/ml | 2 | | eptifibatide intravenous solution 20 mg/10ml, 200 mg/100ml, 75 mg/100ml | GM | |
| trihexyphenidyl hcl oral tablet 2 mg, 5 mg | 2 | | INTEGRILIN INTRAVENOUS SOLUTION 20 MG/10ML, 200 MG/100ML, 75 MG/100ML | GM | |
| XADAGO ORAL TABLET 100 MG, 50 MG | 4 | | KENGREAL INTRAVENOUS SOLUTION RECONSTITUTED 50 MG | GM | |
| ZELAPAR ORAL TABLET DISPERSIBLE 1.25 MG | 4 | | | | |
| Antiplatelets | | | | | |
| AGGRASTAT INTRAVENOUS CONCENTRATE 3.75 MG/15ML | GM | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------------------------------------|-----------|-----------------------------------------------|
| PLAVIX ORAL TABLET 75 MG | 4 | Brand penalty applies |
| prasugrel hcl oral tablet 10 mg, 5 mg | 2 | |
| ZONTIVITY ORAL TABLET 2.08 MG | 4 | |
| Antipsychotics - Drugs for Mood Disorders | | |
| ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE 300 MG, 400 MG | 5 | |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 300 MG, 400 MG | 5 | |
| ABILIFY MYCITE MAINTENANCE KIT ORAL TABLET THERAPY PACK 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG | 4 | QL (30 EA per 30 days) |
| ABILIFY MYCITE STARTER KIT ORAL TABLET THERAPY PACK 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG | 4 | QL (60 EA per 365 days) |
| ABILIFY ORAL TABLET 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG | 4 | Brand penalty applies; QL (30 EA per 30 days) |
| ADASUVE INHALATION AEROSOL POWDER BREATH ACTIVATED 10 MG | GM | |
| aripiprazole oral solution 1 mg/ml | 2 | |
| aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg | 2 | QL (30 EA per 30 days) |

| Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------------------------------------------|-----------|------------------------|
| aripiprazole oral tablet dispersible 10 mg, 15 mg | 2 | QL (30 EA per 30 days) |
| ARISTADA INITIO INTRAMUSCULAR PREFILLED SYRINGE 675 MG/2.4ML | 5 | |
| ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 1064 MG/3.9ML, 441 MG/1.6ML, 662 MG/2.4ML, 882 MG/3.2ML | 5 | |
| asenapine maleate sublingual tablet sublingual 10 mg, 2.5 mg, 5 mg | 2 | PA |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG | 4 | PA |
| chlorpromazine hcl injection solution 25 mg/ml, 50 mg/2ml | GM | |
| chlorpromazine hcl oral concentrate 100 mg/ml, 30 mg/ml | GM | |
| chlorpromazine hcl oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg | 2 | |
| clozapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg | 2 | |
| clozapine oral tablet dispersible 100 mg, 12.5 mg, 150 mg, 200 mg, 25 mg | 2 | |
| CLOZARIL ORAL TABLET 100 MG, 200 MG, 25 MG, 50 MG | 4 | Brand penalty applies |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 4 | PA |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|------------------------------------------------------------------|-----------|-----------------------|------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------------------------------|
| FANAPT TITRATION PACK ORAL TABLET 1 & 2 & 4 & 6 MG | 4 | PA | INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1092 MG/3.5ML, 1560 MG/5ML | 5 | |
| fluphenazine decanoate injection solution 25 mg/ml | GM | | INVEGA ORAL TABLET EXTENDED RELEASE 24 HOUR 1.5 MG, 3 MG, 6 MG, 9 MG | 4 | Brand penalty applies; QL (30 EA per 30 days) |
| fluphenazine hcl injection solution 2.5 mg/ml | GM | | INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML, 156 MG/ML, 234 MG/1.5ML, 39 MG/0.25ML, 78 MG/0.5ML | 5 | |
| fluphenazine hcl oral concentrate 5 mg/ml | 2 | | INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML, 410 MG/1.32ML, 546 MG/1.75ML, 819 MG/2.63ML | 5 | |
| fluphenazine hcl oral elixir 2.5 mg/5ml | 2 | | LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG | 4 | PA |
| fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg | 2 | | loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg | 2 | |
| GEODON INTRAMUSCULAR SOLUTION RECONSTITUTED 20 MG | GM | | molindone hcl oral tablet 10 mg, 25 mg, 5 mg | 2 | |
| GEODON ORAL CAPSULE 20 MG, 40 MG, 60 MG, 80 MG | 4 | Brand penalty applies | NUPLAZID ORAL CAPSULE 34 MG | 5 | PA |
| HALDOL DECANOATE INTRAMUSCULAR SOLUTION 100 MG/ML, 50 MG/ML | GM | | NUPLAZID ORAL TABLET 10 MG | 5 | PA |
| HALDOL INJECTION SOLUTION 5 MG/ML | GM | | olanzapine intramuscular solution reconstituted 10 mg | GM | |
| haloperidol decanoate intramuscular solution 100 mg/ml, 50 mg/ml | GM | | | | |
| haloperidol lactate injection solution 5 mg/ml | GM | | | | |
| haloperidol lactate oral concentrate 2 mg/ml | 2 | | | | |
| haloperidol oral tablet 0.5 mg, 1 mg, 2 mg, 5 mg | 1 | | | | |
| haloperidol oral tablet 10 mg, 20 mg | 2 | | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------------------------------------|-----------|------------------------|----------------------------------------------------------------------------------------|-----------|-----------------------------------------------|
| olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg | 2 | | risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg | 1 | |
| olanzapine oral tablet dispersible 10 mg, 15 mg, 20 mg, 5 mg | 2 | | risperidone oral tablet dispersible 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg | 2 | |
| paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg, 6 mg, 9 mg | 2 | QL (30 EA per 30 days) | SAPHRIS SUBLINGUAL TABLET SUBLINGUAL 2.5 MG, 5 MG | 4 | PA; Brand penalty applies |
| PERSERIS SUBCUTANEOUS PREFILLED SYRINGE 120 MG, 90 MG | 5 | | SAPHRIS TABLET SUBLINGUAL 10 MG SUBLINGUAL 10 MG | 4 | PA; Brand penalty applies |
| pimozide oral tablet 1 mg, 2 mg | 2 | | SAPHRIS TABLET SUBLINGUAL 10 MG SUBLINGUAL 10 MG | 4 | PA |
| quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg, 300 mg, 400 mg, 50 mg | 2 | QL (30 EA per 30 days) | SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24HR, 5.7 MG/24HR, 7.6 MG/24HR | 4 | PA |
| quetiapine fumarate oral tablet 100 mg, 150 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg | 2 | | SEROQUEL ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 400 MG, 50 MG | 4 | Brand penalty applies |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG | 4 | PA | SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HOUR 150 MG, 200 MG, 300 MG, 400 MG, 50 MG | 4 | Brand penalty applies; QL (30 EA per 30 days) |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 12.5 MG, 25 MG, 37.5 MG, 50 MG | 5 | | thioridazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg | 2 | |
| RISPERDAL ORAL SOLUTION 1 MG/ML | 4 | Brand penalty applies | thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg | 2 | |
| RISPERDAL ORAL TABLET 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG | 4 | Brand penalty applies | trifluoperazine hcl oral tablet 1 mg, 10 mg, 2 mg, 5 mg | 2 | |
| risperidone oral solution 1 mg/ml | 2 | | VERSACLOZ ORAL SUSPENSION 50 MG/ML | 4 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------|-----------|---------------------------|---------------------------------------------------------------------------------------|-----------|----------------------------------------|
| FOSCAVIR INTRAVENOUS SOLUTION 6000 MG/250ML | GM | | INTRON A INJECTION SOLUTION RECONSTITUTED 10000000 UNIT, 18000000 UNIT, 50000000 UNIT | 6 | PA; Specialty Medical |
| FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED 90 MG | 6 | | INVIRASE ORAL TABLET 500 MG | 3 | |
| GANCICLOVIR INTRAVENOUS SOLUTION 500 MG/250ML | GM | | ISENTRESS HD ORAL TABLET 600 MG | 3 | |
| ganciclovir sodium intravenous solution 500 mg/10ml | GM | | ISENTRESS ORAL PACKET 100 MG | 4 | |
| ganciclovir sodium intravenous solution reconstituted 500 mg | GM | | ISENTRESS ORAL TABLET 400 MG | 3 | |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 6 | | ISENTRESS ORAL TABLET CHEWABLE 100 MG, 25 MG | 4 | |
| HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG | 5 | PA | JULUCA ORAL TABLET 50-25 MG | 6 | |
| HARVONI ORAL TABLET 45-200 MG, 90-400 MG | 5 | PA | KALETRA ORAL SOLUTION 400-100 MG/5ML | 4 | Brand penalty applies |
| HEPSERA ORAL TABLET 10 MG | 4 | PA; Brand penalty applies | KALETRA ORAL TABLET 100-25 MG, 200-50 MG | 3 | Brand penalty applies |
| INTELENCE ORAL TABLET 100 MG, 200 MG | 4 | Brand penalty applies | LAGEVRIO ORAL CAPSULE 200 MG | 4 | QL (8 EA per 1 day); AL (Min 18 Years) |
| INTELENCE ORAL TABLET 25 MG | 4 | | lamivudine oral solution 10 mg/ml | 2 | |
| INTRON A INJECTION SOLUTION 10000000 UNIT/ML, 6000000 UNIT/ML | 6 | PA; Specialty Medical | lamivudine oral tablet 100 mg, 150 mg, 300 mg | 2 | |
| | | | lamivudine-zidovudine oral tablet 150-300 mg | 2 | |
| | | | LEDIPASVIR-SOFOSBUVIR ORAL TABLET 90-400 MG | 5 | PA |
| | | | LEXIVA ORAL SUSPENSION 50 MG/ML | 4 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------|-----------|-------------------------|---------------------------------------------------|-----------|------------------------------------------------|
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5 MG/ACT | 4 | QL (20 EA per 180 days) | SELZENTRY ORAL TABLET 25 MG, 75 MG | 4 | |
| REMDESIVIR INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 6 | Specialty Medical | SOFOSBUVIR-VELPATASVIR ORAL TABLET 400-100 MG | 5 | PA |
| RETROVIR INTRAVENOUS SOLUTION 10 MG/ML | GM | | SOVALDI ORAL PACKET 150 MG, 200 MG | 6 | PA |
| RETROVIR ORAL CAPSULE 100 MG | 4 | Brand penalty applies | SOVALDI ORAL TABLET 200 MG, 400 MG | 6 | PA |
| RETROVIR ORAL SYRUP 50 MG/5ML | 4 | Brand penalty applies | stavudine oral capsule 15 mg, 20 mg, 30 mg, 40 mg | 2 | |
| REYATAZ ORAL CAPSULE 150 MG, 200 MG, 300 MG | 4 | Brand penalty applies | STRIBILD ORAL TABLET 150-150-200-300 MG | 6 | |
| REYATAZ ORAL PACKET 50 MG | 4 | | SUSTIVA ORAL CAPSULE 200 MG, 50 MG | 4 | Brand penalty applies |
| ribavirin inhalation solution reconstituted 6 gm | 6 | PA; Specialty Medical | SUSTIVA ORAL TABLET 600 MG | 4 | Brand penalty applies |
| ribavirin oral capsule 200 mg | 5 | PA | SYMFI LO ORAL TABLET 400-300-300 MG | 6 | |
| ribavirin oral tablet 200 mg | 5 | PA | SYMFI ORAL TABLET 600-300-300 MG | 6 | |
| rimantadine hcl oral tablet 100 mg | 2 | | SYMTUZA ORAL TABLET 800-150-200-10 MG | 6 | |
| ritonavir oral tablet 100 mg | 2 | | TAMIFLU ORAL CAPSULE 30 MG | 4 | Brand penalty applies; QL (20 EA per 180 days) |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HOUR 600 MG | 6 | | TAMIFLU ORAL CAPSULE 45 MG, 75 MG | 4 | Brand penalty applies; QL (10 EA per 180 days) |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 4 | | | | |
| SELZENTRY ORAL TABLET 150 MG, 300 MG | 4 | Brand penalty applies | | | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|--------------------------------------------------------------------|-----------|-------------------------------------------------|---------------------------------------------------------|-----------|-----------------------|
| TAMIFLU ORAL SUSPENSION RECONSTITUTED 6 MG/ML | 4 | Brand penalty applies; QL (120 ML per 180 days) | valganciclovir hcl oral solution reconstituted 50 mg/ml | 5 | |
| TEMIXYS ORAL TABLET 300-300 MG | 6 | | valganciclovir hcl oral tablet 450 mg | 5 | |
| tenofovir disoproxil fumarate oral tablet 300 mg | 2 | | VALTREX ORAL TABLET 1 GM, 500 MG | 4 | Brand penalty applies |
| TIVICAY ORAL TABLET 10 MG, 25 MG, 50 MG | 6 | | VEKLURY INTRAVENOUS SOLUTION 100 MG/20ML | 6 | Specialty Medical |
| TIVICAY PD ORAL TABLET SOLUBLE 5 MG | 6 | | VEKLURY INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 6 | Specialty Medical |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 6 | | VEMLIDY ORAL TABLET 25 MG | 5 | PA |
| TRIUMEQ PD ORAL TABLET SOLUBLE 60-5-30 MG | 6 | | VIEKIRA PAK ORAL TABLET THERAPY PACK 12.5-75-50 | 6 | PA |
| TRIZIVIR ORAL TABLET 300-150-300 MG | 4 | | VIRACEPT ORAL TABLET 250 MG, 625 MG | 4 | |
| TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33ML | 6 | Specialty Medical | VIRAMUNE ORAL SUSPENSION 50 MG/5ML | 4 | Brand penalty applies |
| TRUVADA ORAL TABLET 100-150 MG, 133-200 MG, 167-250 MG, 200-300 MG | 6 | PV* | VIRAMUNE XR ORAL TABLET EXTENDED RELEASE 24 HOUR 400 MG | 4 | Brand penalty applies |
| TYBOST ORAL TABLET 150 MG | 4 | ST | VIRAZOLE INHALATION SOLUTION RECONSTITUTED 6 GM | 6 | PA; Specialty Medical |
| valacyclovir hcl oral tablet 1 gm, 500 mg | 2 | | VIREAD ORAL POWDER 40 MG/GM | 4 | |
| VALCYTE ORAL SOLUTION RECONSTITUTED 50 MG/ML | 6 | | VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | 4 | |
| VALCYTE ORAL TABLET 450 MG | 6 | | VIREAD ORAL TABLET 300 MG | 4 | Brand penalty applies |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------|-----------|-----------------------------------------------|-----------------------------------------------------------------------------|-----------|-----------------------|
| VOCABRIA ORAL TABLET 30 MG | 6 | | alprazolam intensol oral concentrate 1 mg/ml | 2 | |
| VOSEVI ORAL TABLET 400-100-100 MG | 6 | PA | alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg | 2 | |
| XOFLUZA (40 MG DOSE) ORAL TABLET THERAPY PACK 1 X 40 MG, 2 X 20 MG | 4 | QL (2 EA per 180 days) | alprazolam oral tablet dispersible 0.25 mg, 0.5 mg, 1 mg, 2 mg | 2 | ST |
| XOFLUZA (80 MG DOSE) ORAL TABLET THERAPY PACK 1 X 80 MG, 2 X 40 MG | 4 | QL (2 EA per 180 days) | alprazolam xr oral tablet extended release 24 hour 0.5 mg, 1 mg, 2 mg, 3 mg | 2 | |
| ZEPATIER ORAL TABLET 50-100 MG | 6 | PA | ATIVAN INJECTION SOLUTION 2 MG/ML, 4 MG/ML | GM | |
| ZIAGEN ORAL SOLUTION 20 MG/ML | 4 | Brand penalty applies | ATIVAN ORAL TABLET 0.5 MG, 1 MG, 2 MG | 4 | Brand penalty applies |
| ZIAGEN ORAL TABLET 300 MG | 4 | Brand penalty applies | buspirone hcl oral tablet 10 mg, 15 mg, 5 mg | 1 | |
| zidovudine oral capsule 100 mg | 2 | | buspirone hcl oral tablet 30 mg, 7.5 mg | 2 | |
| zidovudine oral syrup 50 mg/5ml | 2 | | BYFAVO INTRAVENOUS SOLUTION RECONSTITUTED 20 MG | GM | |
| zidovudine oral tablet 300 mg | 2 | | chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg | 2 | |
| ZOVIRAX EXTERNAL CREAM 5 % | 4 | Brand penalty applies | clonazepam oral tablet 0.5 mg, 1 mg, 2 mg | 2 | |
| ZOVIRAX EXTERNAL OINTMENT 5 % | 4 | Brand penalty applies; QL (15 GM per 30 days) | clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg | 2 | |
| ZOVIRAX ORAL SUSPENSION 200 MG/5ML | 4 | Brand penalty applies | clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg | 2 | |
| Anxiolytics - Drugs for Anxiety | | | diazepam intensol oral concentrate 5 mg/ml | 2 | |
| alprazolam er oral tablet extended release 24 hour 0.5 mg, 1 mg, 2 mg, 3 mg | 2 | | diazepam oral concentrate 5 mg/ml | 2 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------------|-----------|------------------------------------------------|
| PROCENTRA ORAL SOLUTION 5 MG/5ML | 4 | Brand penalty applies |
| QELBREE ORAL CAPSULE EXTENDED RELEASE 24 HOUR 100 MG, 150 MG, 200 MG | 4 | |
| QUILLICHEW ER ORAL TABLET CHEWABLE EXTENDED RELEASE 20 MG, 30 MG, 40 MG | 4 | PA; AL (Min 6 Years and Max 12 Years) |
| QUILLIVANT XR ORAL SUSPENSION RECONSTITUTED ER 25 MG/5ML | 4 | PA; QL (180 ML per 30 days) |
| relexxii oral tablet extended release 72 mg | 2 | QL (1 EA per 1 day) |
| RITALIN LA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 10 MG, 20 MG, 30 MG, 40 MG | 4 | Brand penalty applies; QL (30 EA per 30 days) |
| RITALIN ORAL TABLET 10 MG | 4 | Brand penalty applies; QL (180 EA per 30 days) |
| RITALIN ORAL TABLET 20 MG | 4 | Brand penalty applies |
| RITALIN ORAL TABLET 5 MG | 4 | Brand penalty applies; QL (90 EA per 30 days) |
| STRATTERA ORAL CAPSULE 10 MG, 18 MG, 25 MG | 4 | Brand penalty applies; QL (60 EA per 30 days) |

| Drug Name | Drug Tier | Notes |
|-----------------------------------------------------------------------|-----------|---------------------------------------------------------------|
| STRATTERA ORAL CAPSULE 100 MG, 40 MG, 60 MG, 80 MG | 4 | Brand penalty applies; QL (30 EA per 30 days) |
| VYVANSE ORAL CAPSULE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG, 70 MG | 4 | QL (30 EA per 30 days) |
| VYVANSE ORAL TABLET CHEWABLE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG | 4 | PA; QL (30 EA per 30 days); AL (Min 6 Years and Max 12 Years) |
| ZENZEDI TABLET 10 MG ORAL 10 MG | 4 | Brand penalty applies; QL (180 EA per 30 days) |
| ZENZEDI TABLET 10 MG ORAL 10 MG | 4 | Brand penalty applies; QL (2 EA per 1 day) |
| ZENZEDI TABLET 15 MG ORAL 15 MG | 4 | Brand penalty applies |
| ZENZEDI TABLET 15 MG ORAL 15 MG | 4 | Brand penalty applies; QL (60 EA per 30 days) |
| ZENZEDI TABLET 2.5 MG ORAL 2.5 MG | 4 | |
| ZENZEDI TABLET 2.5 MG ORAL 2.5 MG | 4 | QL (60 EA per 30 days) |
| ZENZEDI TABLET 20 MG ORAL 20 MG | 4 | Brand penalty applies |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------|-----------|------------------------------------------------|-------------------------------------------------------------------------------|-----------|-----------------------|
| ZENZEDI TABLET 20 MG ORAL 20 MG | 4 | Brand penalty applies; QL (60 EA per 30 days) | BAFIERTAM ORAL CAPSULE DELAYED RELEASE 95 MG | 5 | |
| ZENZEDI TABLET 30 MG ORAL 30 MG | 4 | Brand penalty applies | BETASERON SUBCUTANEOUS KIT 0.3 MG | 5 | |
| ZENZEDI TABLET 30 MG ORAL 30 MG | 4 | Brand penalty applies; QL (60 EA per 30 days) | dalfampridine er oral tablet extended release 12 hour 10 mg | 6 | PA |
| ZENZEDI TABLET 5 MG ORAL 5 MG | 4 | Brand penalty applies; QL (180 EA per 30 days) | dimethyl fumarate oral capsule delayed release 120 mg, 240 mg | 5 | |
| ZENZEDI TABLET 5 MG ORAL 5 MG | 4 | Brand penalty applies; QL (2 EA per 1 day) | dimethyl fumarate starter pack oral 120 & 240 mg | 5 | |
| ZENZEDI TABLET 7.5 MG ORAL 7.5 MG | 4 | | EXTAVIA SUBCUTANEOUS KIT 0.3 MG | 6 | |
| ZENZEDI TABLET 7.5 MG ORAL 7.5 MG | 4 | QL (60 EA per 30 days) | fingolimod hcl oral capsule 0.5 mg | 6 | |
| Central Nervous System Agents - Drugs for Multiple Sclerosis | | | GILENYA ORAL CAPSULE 0.25 MG, 0.5 MG | 6 | |
| AUBAGIO ORAL TABLET 14 MG, 7 MG | 6 | | glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml | 5 | |
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 30 MCG/0.5ML | 5 | | glatopa subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml | 5 | |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 30 MCG/0.5ML | 5 | | KESIMPTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 20 MG/0.4ML | 6 | |
| | | | LEMTRADA INTRAVENOUS SOLUTION 12 MG/1.2ML | 6 | PA; Specialty Medical |
| | | | MAVENCLAD ORAL TABLET THERAPY PACK 10 MG | 6 | PA |
| | | | MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG | 6 | |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

| Drug Name | Drug Tier | Notes | Drug Name | Drug Tier | Notes |
|---------------------------------------------------------------------------------|-----------|-----------------------|------------------------------------------------------------------------------------|-----------|-----------------------|
| MAYZENT STARTER PACK ORAL TABLET THERAPY PACK 0.25 MG, 12 X 0.25 MG | 6 | | REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR 22 MCG/0.5ML, 44 MCG/0.5ML | 6 | |
| OCREVUS INTRAVENOUS SOLUTION 300 MG/10ML | 6 | PA; Specialty Medical | REBIF REBIDOSE TITRATION PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 6X8.8 & 6X22 MCG | 6 | |
| PLEGRIDY INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 125 MCG/0.5ML | 6 | | REBIF SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 22 MCG/0.5ML, 44 MCG/0.5ML | 6 | |
| PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PEN-INJECTOR 63 & 94 MCG/0.5ML | 6 | | REBIF TITRATION PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6X8.8 & 6X22 MCG | 6 | |
| PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 63 & 94 MCG/0.5ML | 6 | | TECFIDERA ORAL 120 & 240 MG | 5 | |
| PLEGRIDY SUBCUTANEOUS SOLUTION PEN-INJECTOR 125 MCG/0.5ML | 6 | | TECFIDERA ORAL CAPSULE DELAYED RELEASE 120 MG, 240 MG | 5 | |
| PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 125 MCG/0.5ML | 6 | | TYSABRI INTRAVENOUS CONCENTRATE 300 MG/15ML | 6 | PA; Specialty Medical |
| PONVORY ORAL TABLET 20 MG | 6 | | VUMERITY ORAL CAPSULE DELAYED RELEASE 231 MG | 6 | |
| PONVORY STARTER PACK ORAL TABLET THERAPY PACK 2-3-4-5-6-7-8-9 & 10 MG | 6 | | ZEPOSIA 7-DAY STARTER PACK ORAL CAPSULE THERAPY PACK 4 X 0.23MG & 3 X 0.46MG | 6 | PA |
| | | | ZEPOSIA ORAL CAPSULE 0.92 MG | 6 | PA |

Effective December 1, 2022

PA=Prior Auth Required; ST = Step Therapy; QL = Quantity Limits; AL = Age Limit; PV = Preventive; PV* = Preventive if member meets criteria

